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FUNCTION OF ZNF668 IN CANCER DEVELOPMENT

Publication No. ________
Ruozhen Hu, M.S.
Supervisory Professor: Shiaw-Yih Lin, Ph.D.
Human cancer develops as a result of accumulation of mutations in
oncogenes and tumor suppressor genes. Zinc finger protein 668 (ZNF668) has
recently been identified and validated as one of the highly mutated genes in
breast cancer, but its function is entirely unknown. Here, we report two major
functions of ZNF668 in cancer development.
(1) ZNF668 functions as a tumor suppressor by regulating p53
protein stability and function. We demonstrate that ZNF668 is a nucleolar
protein that physically interacts with both MDM2 and p53. By binding to MDM2,
ZNF668 regulates MDM2 autoubiquitination and prevents MDM2-mediated p53
ubiquitination and degradation; ZNF668 deficiency impairs DNA damageinduced p53 stabilization. Notably, ZNF668 effectively suppresses breast cancer
cell proliferation and transformation in vitro and tumorigenicity in vivo.
Consistently, ZNF668 knockdown readily transforms normal mammary epithelial
cells. Together, our studies identify ZNF668 as a novel breast tumor suppressor
gene that acts at least in part by regulating the stability and function of p53.
(2) ZNF668 functions as a DNA repair protein by regulating histone
acetylation. DNA repair proteins need to access the chromatin by chromatin

iv

modification or remodeling to use DNA template within chromatin. Dynamic
posttranslational modifications of histones are critical for cells to relax chromatin
in DNA repair. However, the precise underlying mechanism mediating enzymes
responsible for these modifications and their recruitment to DNA lesions remains
poorly understood. We observed ZNF668 depletion causes impaired chromatin
relaxation as a result of impaired DNA-damage induced histone H2AX hyperacetylation. This results in the decreased recruitment of repair proteins to DNA
lesions, defective homologous recombination (HR) repair and impaired cell
survival after DNA damage, albeit with the presence of a functional ATM/ATR
dependent DNA-damage signaling cascade. Importantly, the impaired loading of
repair proteins and the defect in DNA repair in ZNF668-deficient cells can be
counteracted by chromatin relaxation, indicating that the DNA-repair defect that
was observed in the absence of ZNF668 is due to impeded chromatin
accessibility at sites of DNA breaks. Our findings therefore identify ZNF668 as a
key molecule that links chromatin relaxation with response to DNA damage in
the control of DNA repair.
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PART I. ROLE OF ZNF668 IN P53 REGULATION AND BREAST CANCER
TUMORIGENESIS

CHAPTER 1 INTRODUCTION

1.1 Breast Cancer and Genetic Aberrations
Breast cancer continues to be the leading cause of cancer death in
women in the United States and worldwide (Jemal et al., 2010). It is expected to
account for 15% of all female cancer deaths in United States in 2010 (Jemal et
al., 2010). The main types of breast cancer are ductal carcinoma and lobular
carcinoma. The development of breast cancer is often attributed to many risk
factors including sex, age, higher hormone levels, race and family history of
breast cancer (McPherson et al., 2000).
Breast cancer development, like other types of cancer, is the
consequence of the accumulation of multiple gene mutations (Wooster et al.,
2003). Breast cancer risk is typically increased in individuals with family history.
Although researchers found that the mutations in high-penetrance BRCA1 and
BRCA2 genes contribute to breast cancer development, these mutations only
account for less than 20% of the patients with familial risk (Anglian Breast
Cancer Study Group, 2000; Wooster et al., 2003). These findings suggest that
additional genetic alterations are required for the development of breast cancer.
Identifying these relatively low-penetrance genes will help people to better
understand the implication of genetic alterations in breast cancer development.
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The high-throughput genotyping analysis and understand of genetic
variation patterns in human genome have advanced the research of genetic
abberiations in human cancer. The availability of the human genome sequence
highthroughput analysis of tumor genome, and powerful computational methods
make it possible to identify new candidate cancer genes and somatic changes in
human cancers. For example, researchers investigated the genetic alterations in
the coding sequences of well annotated genes and they identified the regions of
the genome that have the potential to cause cancer development (Sjoblom et al.,
2006; Wood et al., 2007). These studies will facilitate the design of targeted
therapeutic approaches and provide key insights into the mechanisms
underlying tumorigenesis.

1.2

Zinc Finger Protein 668 and its somatic mutations in patient breast

cancer samples
The accumulation of mutations in oncogenes and tumor suppressor
genes accounts for human cancer development (Vogelstein and Kinzler 2004).
Thus, understanding how these genetic alterations contribute to human cancer
development is a powerful tool to study the mechanisms underlying
tumorigenesis and to identify new targets for clinical intervention.

2

Figure 1. Ten leading cancer types for the estimated new cancer cases and
deaths by sex, 2010. (Jemal et al., 2010).

Through genomewide gene sequencing, many genes that are frequently
mutated in breast tumor samples have been discovered (Sjoblom et al., 2006).
Among these mutated genes, a hypothetical protein (FLJ13479) later named
zinc finger protein 668 (ZNF668) was identified, and validated as a frequently
mutated gene in breast cancer (Sjoblom et al., 2006). ZNF668 gene mutations
were found in four out of thirty-five breast cancer samples analyzed (11.4%)
(Sjoblom et al., 2006). Since ZNF668 is frequently mutated in breast cancer, we
3

suspect that ZNF668 might be an important breast cancer gene that contributes
to breast cancer development.

Figure 2. Conserved domain in zinc finger protein 668.

ZNF668 belongs to the kruppel C2H2-type zinc-finger protein family and
contains 16 C2H2-type zinc fingers (Figure 2). So far, the function of ZNF668
has remained entirely unexplored. To understand the role of ZNF668 in breast
cancer development, we used a proteomics-based approach to systematically
identify ZNF668-binding proteins (Figure 3). A nucleolar protein, nucleophosmin
(NPM, B23), was pulled down by ZNF668 (Figure 3), and interaction between
ZNF668 and NPM was confirmed by immunoprecipitation analysis later.
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Figure 3. Silver staining of the ZNF668 complex separated by SDS-PAGE. The
whole cell extracts were prepared from U2OS cells transiently transfected with
empty vector or Flag-ZNF668. Cell lysates were mixed with M2-Flag agrose
beads and the protein complex was pulled down and eluted with M2-Flag
peptide. Flag-ZNF668 and nucleophosmin are indicated.

1.3

Role of nucleolus and nucleolar proteins in p53 regulation and

tumorigenesis.
The connection between nucleolus function and tumorigenesis is now
being appreciated. Although nucleolus is well known as the site for production
and assembly of ribosome components, recent studies suggested that nucleolar
components were also involved in cancer development events such as p53
stabilization and p53 induced cell cycle arrest (Lohrum et al., 2003; Dai et al.,
2006 and Pestov et al., 2001).
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NPM is a nucleolar phosphoprotein that constantly shuttles between the
nucleus and cytoplasm (Yun et al., 2003; Grisendi et al., 2006). It is involved in
ribosome biogenesis and can function as either an oncogene or a tumor
suppressor depending on the context (Grisendi et al., 2006). Recent studies
showed that NPM was involved in regulation of the p53 tumor suppressor
protein function (Colombo et al., 2002; Kurki et al., 2004). NPM binds MDM2 and
protects p53 from MDM2-mediated degradation (Kurki et al., 2004). The
nucleolus, where most NPM resides, functions as a cellular stress sensor that
integrates a variety of cellular stresses to trigger p53 responses and regulate the
role of p53 in tumor suppression (Pestov et al., 2001; Rubbi and Milner 2003;
Horn and Vousden 2004); the nucleolus plays an important role in p53
stabilization under stress conditions (Pestov et al., 2001). Indeed, subcellular
redistribution of NPM and other nucleolar proteins, such as ARF, has regulated
p53 function (Itahana et al., 2003; Bertwistle et al., 2004; Kurki et al., 2004;
Korgaonkar et al., 2005; Grisendi et al., 2006).
The nucleolar ARF-MDM2-p53 feedback loop regulation also represents
another example to explain the connection between nucleolar stress and
tumorigenesis. Tumor suppressor ARF is a nucleolar protein and its association
with MDM2 could contribute to the localization and retention of MDM2 to the
nucleolus thereby sequester MDM2 activity and stabilize p53 (Zhang et al., 1998;
Sherr et al., 2000; Honda et al., 1999; Kamijo et al., 1999; Stott et al., 1998 and
Pomerantz et al., 1998). Under cellular stress, disruption of the nucleolar
function is responsible for the redistribution of nucleolar proteins to stabilize and
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regulate p53 function (Rubbi et al., 2003). Therefore, the nucleolus is proposed
to be a sensor for integrating variety of cellular stresses together to trigger p53
responses and regulate its role in tumorigenesis (Pestov et al., 2001; Rubbi et
al., 2003 and Horn et al., 2004).
Thus, the connection between nucleolus and regulation of p53 is highly
implicated in tumorigenesis. The interaction between ZNF668 and NPM and the
nucleolar localization of ZNF668 (see Figure 4) suggested that ZNF668 might be
involved in p53 regulation.

1.4

p53 and tumor suppression
The tumor suppressor protein p53 was first identified in 1979 as a cellular

protein that bound to the simian virus (SV40) large T antigen and accumulated in
the nuclei of cancer cells (Lane et al., 1979). The real role of p53 was uncovered
until 10 years after its discovery. At first, p53 was thought to be an oncogene
because it present at increased levels in transformed cells (Vogelstein, 2001).
However, later it was found that the p53 people were studying was in fact a
mutant form because the p53 cDNA was cloned from cancer sample and it
contained missense mutations. Since 1989, research into p53 supported that
one of the major function of wild type p53 was tumor suppression.
In normal cells, p53 level is tightly controlled by its negative regulator, the
E3 ubiquitin ligase MDM2 (Haupt et al., 1997; Kubbutat et al., 1997; Nampoothiri
1998; Kubbutat, et al. 1999). Ubiquitination of p53 by MDM2 leads to export of
p53 from the nucleus to the cytoplasm followed by proteasomal degradation
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(Boyd et al., 2000; Geyer et al., 2000). Under cellular stresses—such as genetic
alterations,

DNA

damage

stress,

oncogene

activation,

and

hypoxia—

dissociation of MDM2 and p53 stabilizes p53 protein, and stabilization of p53 in
turn leads to various cellular responses, including cell apoptosis, cell cycle
arrest, cell senescence and DNA damage repair (Vousden and Lu 2002).
p53 plays a critical role in preventing damaged cells from transforming
into malignant cells (Ryan et al., 2001). The most important pathways involved in
tumor suppression that are activated by p53 include apoptosis, cell-cycle arrest,
senescence and DNA repair.
If the DNA damage is too severe to be repaired, the activated p53 can
initiate cell apoptosis, the programmed cell death (Jian et al., 2003). The p53
induced apoptosis can be explained by its activation of expression of various
downstream target genes including p53AIP, bax, Fas/APO1, Tsp1, IGF-BP3,
PUMA and others (Hickman et al., 2002). The activated p53 activates
expression of p21 which is an inhibitor of cyclin-dependent kinases (CDKs). p21
binds to G1-to-S CDK complexes and inhibits G1-to-S transition (Harper et al.,
1993). p53 may also inhibit G2-to-M transition by regulation of protein 14-3-3σ,
which sequesters cyclin B1–CDK1 complexes outside the nucleus and stop cells
in G2 phase (Hermeking et al., 1997). In tumors, mutant p53 can no longer bind
DNA in an effective way and the downstream regulation of p21 failed to stop cell
division, thus contributed to tumor formation by the uncontrolled cells division.
DNA damage, oncogene activation or telomere dysfunction can lead to
the activation of p53 (Deng et al., 2008). Activated p53 can trigger senescence,
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a permanent cell cycle arrest, and inhibit tumor progression. Senescence is
likely to result from changes in the expression of a number of proteins such as
the plasminogen activator inhibitor 1 (PAI-1) (Kortlever et al., 2006). p21 is
another important player in response to p53-mediated senescence (Harper et
al., 1993). In mouse models, reactivation of p53 in carcinomas and sarcomas
triggers senescence rather than apoptosis (Artandi et al., 2005). In vivo study
indicated that p53 induced senescence caused the subsequent engagement of
the immune system and could result in tumor clearance (Xue et al., 2007).
The p53 protein is important in maintaining genetic stability. It may involve
the induction of genes that regulate nucleotide-excision repair of DNA (Seo et
al., 2002), chromosomal recombination and chromosome segregation. Further
evidence for a role for p53 in DNA repair comes from the induction of a specific
ribonucleotide reductase gene (p53R2) by p53 after DNA damage (Xue et al.,
2007). p53 may also facilitate the homologous recombination repair of double
strand breaks through the regulation of the fidelity of Rad51-dependent HR
repair pathway (Bertrand et al., 2004).

1.5

Hypothesis and project goals
In our preliminary data, ZNF668 was associated with many nucleolar

proteins including, nucleophosmin (NPM) and nucleostemin (NS), two proteins
that bind and regulate p53 protein. We also identified ZNF668 as a novel p53
binding protein localized in the nucleoli of breast cancer cells. Therefore, we
hypothesize that ZNF668 plays a critical role in regulation of p53 tumor
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suppressor activity for breast tumor suppression. We suspect that ZNF668 may
contribute to breast cancer suppression at least in part through regulation of
p53.
In this part of study, we aim to demonstrate the functional interaction
among ZNF668, p53, and MDM2. We will try to study the role of ZNF668 as a
novel tumor suppressor gene in breast cancer and reveal its mechanistic
function in regulating the MDM2-p53 interaction.

10

CHAPTER 2 MATERIALS AND METHODS

2.1

Cell Culture and Transfection
U2OS cells and breast cancer cells were purchased from the American

Type Culture Collection. U2OS cells were maintained in McCoy's 5A medium
(Cellgro) supplemented with 10% fetal bovine serum (FBS) with glutamine,
penicillin, and streptomycin. MCF7, MCF7-control, and MCF7-p53 knockdown
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro)
supplemented with 10% FBS with glutamine, penicillin, and streptomycin.
MCF10A cells were maintained in mammary epithelial growth medium
(Clonetics), a proprietary serum-free medium containing insulin, hydrocortisone,
epidermal growth factor, and bovine pituitary extract. HMECs were grown in
mammary epithelial basal medium supplemented with MEGM SingleQuots
growth factors (Lonza). Cells were incubated at 37°C in a humidified incubator
with 5% CO2 and transfected with Fugene 6 (Roche), Lipofectamine 2000
(Invitrogen) or Oligofectamine (Invitrogen).

2.2

Plasmids
To generate FLAG-ZNF668, V5-ZNF668, and GST-ZNF668 constructs,

full-length ZNF668 cDNA was amplified by polymerase chain reaction (PCR)
and subcloned into pCMV5-3 x FLAG vector (Sigma), pLenti4/TO/V5-DEST
vector (Invitrogen), and pGEX-4T vector (Addgene). The R556Q (Mutant 1) and
A66T (Mutant 2) point mutations were created from 3 x FLAG-ZNF668 using the
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GeneTailor Site-Directed Mutagenesis System (Invitrogen). The FLAG-tagged
ZNF668 deletion mutants ZNF668- Δ 1~ Δ 12 were generated by PCR and
subcloned into 3 x FLAG vector. FLAG-p53 (108038, pcDNA3 FLAG-p53), GSTp53 (10852, p3113 GST-p53), and GST-MDM2 (16237, pGEX-4T MDM2 wildtype) were purchased from Addgene. MDM2 deletion plasmids Δ 58-89, Δ 212296, Δ 222-437, Δ 296-437, and Δ 9 (RING finger domain deletion) were kind
gifts from Dr. Karen Vousdens (The Beatson Institute for Cancer research). The
identity of the plasmids was confirmed by sequencing at the MD Anderson
Cancer Center DNA Analysis Core Facility.

2.3

Antibodies and Reagents
Nucleotides 548-1449 were subcloned into pGEX-4T with the sense

primer 5 -TTTTGGATCCATGGAAGTGGAGGCTGCAGAG-3 and the antisense
primer 5 -TTTTGAATTCGCGCTGGTGGCGAGGGAAGCT-3 , and the protein
product was used for immunization for rabbit polyclonal anti-ZNF668 antibody
(Proteintech Group, Inc.). Anti-FLAG M2-agarose affinity gel was purchased
from Sigma. Anti-p53 (FL-393), anti-MDM2 (SMP14), anti-NPM (C-19), anti-p53
(FL393), and anti-p21(C-19) were purchased from Santa Cruz Biotechnology.
Anti-p53 (DO-1) was purchased from Calbiochem. Anti-phospho-p53–Ser 15
was purchased from Cell Signaling. Anti-ubiquitin (FK2) and an ubiquitinylation
kit were purchased from BioMol. Anti-NS (MAB4311) was purchased from
Chemicon. Anti-V5 (ab9116) and anti-NPM (ab10530) were purchased from
Abcam. Fluorochrome-conjugated secondary antibodies were purchased from
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Jackson ImmunoResearch Laboratories. A thrombine cleavage capture kit was
purchased from Novagen. Cycloheximide was obtained from Sigma and used at
50 μg/ml (U2OS cells) or 20 μg/ml (MCF7 cells). MG132 (carbobenzoxy-Lleucyl-L-leucyl-L-leucine) was obtained from EMD Biosciences and used at 10
μM. Nutlin-3 was purchased from Cayman Chemical and used at 10 μM.

2.4

RNA Interference
ZNF668 knockdown was achieved by RNA interference using either

siRNA (Dharmacon) or a lentiviral vector-based MISSION shRNA (Sigma). The
ON-TARGETplus ZNF668 siRNA duplex and ON-TARGETplus SMARTpool
HDM2 siRNA mix were purchased from Dharmacon Research, Inc. ONTARGETplus nontargeting siRNA was used as a control for the siRNA reactions.
RNA duplexes (final concentration 100 nM) were transfected into the cells using
Oligofectmine (U2OS) or Lipofectamine 2000 (MCF7 & MCF10A) according to
the manufacturer’s protocol (Invitrogen). Cells transfected with ZNF668 siRNA
duplexes were incubated for 2 and 3 days, respectively. A decrease in the
respective protein levels was verified by Western blotting. Lentiviral particles
corresponding to the MISSION shRNA ZNF668 target set were used, as well as
the MISSION nontarget shRNA control. The specificity and efficacy of the
shRNA ZNF668 procedure were controlled with Western blotting after
transduction and puromycin selection in knockdown cells.

2.5

Immunofluorescent Microscopy
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Cells were fixed with 4% paraformaldehyde and then permeabilized with
0.5% NP-40 and 1% Triton X-100. The primary antibodies were as follows:
NPM, C-19; NS, MAB4311; V5-tag, ab9116; p53, FL393; and MDM2, SMP14. In
coimmunostainings, donkey anti-rabbit conjugated Alexa 594, goat anti-rabbit
conjugated Alexa 488, chicken anti-mouse conjugated Alexa 594, or goat antimouse conjugated Alexa 488 (Invitrogen) were used as fluorochromes, and DNA
was stained with 4 ,6-diamidino-2-phenylindole (DAPI, Vector Laboratories).
Absence of cross-reactivity of the antibodies and conjugates was verified in
separate experiments. Images were acquired using a Nikon Eclipse TE200-E
microscope

and

processed

with

IPLab

imaging

software

(BioVision

Technologies).

2.6

Immunoblotting and Immunoprecipitation
Cells were washed in phosphate-buffered saline and lysed in modified

RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 10% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium
orthovanadate, and 1 mM NaF). For nuclear extract preparation, cells were lysed
in (10 mM HEPES [pH 8.0], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol,
and 0.5% NP-40), and nuclear extracts were prepared in nuclear extraction
buffer (20 mmol/L HEPES [pH 7.9], 1.5 mM MgCl2, 100 mM KCl, 420 mM NaCl,
0.2 mM EDTA, and 1 mM dithiothreitol). After clarification, cell lysates were
immunoprecipitated with specific antibodies (NPM, ab10530; ZNF668, rabbit
polyclonal anti-ZNF668 antibody; MDM2, SMP-14; and p53, DO-1). The
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immunocomplexes were collected on Protein A/G plus-conjugated agarose
beads (Santa Cruz Biotechnology). Cellular lysates or immunocomplexes were
separated by 7% or 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis

(SDS-PAGE)

and

transferred

to

Protran

nitrocellulose

membrane (Fisher Scientific). Membranes were blocked in Tris-buffered saline0.1% Tween 20 (TBS-T)/5% (w/v) milk for 1 h at room temperature and were
then incubated with primary antibodies diluted in TBS-T/5% (w/v) milk for 2 h at
room temperature or overnight at 4°C. Subsequently, membranes were washed
with TBS-T and incubated with horseradish peroxidase secondary antibody
(1:5000)

(Jackson

ImmunoResearch)

diluted

in

TBS-T/5%

skim

milk.

Membranes were washed in TBS-T, and bound antibody was detected by
enhanced chemiluminescence (GE Healthcare).

2.7

In Vivo Ubiquitination Assay
For the in vivo p53 ubiquitination assay, FLAG-tagged ZNF668 was

transfected into U2OS cells using Fugene 6 (Roche). Forty-eight hours after
transfection, cells were treated with MG132, harvested, washed with phosphatebuffered saline, pelleted, and lysed in RIPA buffer. The cell lysates were then
subjected to SDS-PAGE, and p53 or MDM2 protein level was normalized so that
there were equal levels of p53 or MDM2 in control cells and ZNF668-expressing
cells. The proportional amounts of cell lysates were incubated with p53 or MDM2
antibody and pulled down using protein A/G beads. Beads were washed three
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times and boiled for 5 min. The boiled samples were separated by SDS-PAGE,
and protein was detected by immunoblotting with anti-ubiquitin antibody.

2.8

Preparation of Recombinant Proteins
The plasmids pGEX-4T-1-ZNF668, pGEX-4T-MDM2, and pGEX-2TK-p53

were used to express recombinant GST-ZNF668, GST-MDM2, and GST-p53 in
Escherichia coli strain BL21 (GE Healthcare). The GST fusion proteins were
expressed by induction for 12 h at 25°C with 0.1 mM isopropyl-1-thio-β-Dgalactopyranoside in strain BL21 and purified using glutathione agarose (Sigma)
according to the manufacturer's instructions. GST fusion proteins harboring p53,
ZNF668, and MDM2 were cleaved and purified with a thrombin cleavage capture
kit.

2.9

In Vitro GST-Protein Binding Assay
Cleaved p53 and MDM2 were purified as described in the preceding

paragraph. GST-ZNF668 was not cleaved. Purified proteins were incubated in
300 ml of binding buffer (25 mM Tris-Cl [pH 7.2], 50 mM NaCl, and 0.2% NP-40)
with continuous shaking. Proteins were recovered (2 h at 4°C) with glutathione
agarose beads (Sigma). Beads were washed three times with 1 ml of washing
buffer (100 mM Tris-Cl [pH 8.0], 100 mM NaCl, and 1% Nonidet P-40) four times
and were eluted with 10 mg/ml fresh-made reduced glutathione (pH 8.0). Eluted
proteins were subjected to SDS-PAGE and Western blotting analysis.
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2.10

Reverse Transcriptase-PCR and PCR
cDNA was transcribed using SuperScript III (Invitrogen) following the

manufacturer's instructions. ZNF668 was amplified by PCR using the primers 5 GGAAGCCAGTGGGGAGAAGGTGTC-3

and 5 -CGCTCGTGGCTCTGGTA

GGAACTG-3 . For amplification of p53, the primers 5 -GCGCACAGA
GGAAGAGAATC-3 and 5 -CCTCATTCAGCTCTCGGAAC-3 were used.

2.11

Luciferase Assay
U2OS cells were transfected with the pG13-LUC reporter vector in the

absence or presence of expression vectors for the indicated proteins or empty
expression vector (3

FLAG). The total amount of expression vector was

constant in all transfections. After 48 h, luciferase activities were determined in
duplicate samples according to the manufacturer’s instructions (Promega). The
relative luciferase activity was assayed by cotransfection of a plasmid for the
expression of renella and normalization for its activity. The fold increase in
relative luciferase activity therefore represented the extent of p53 activation.
Data were presented as the mean ± standard deviation (SD) of three
independent experiments.

2.12

In Vitro Proliferation and Soft Agar Assay
To measure cell proliferation, cells were plated in 96-well plates (200-μl

cell suspensions, 5x103 cells/ml) and allowed to grow for 1 to 4 days. Each day,
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma)
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substrate (2 mg/ml) was added into the culture medium. Four hours later, the
culture medium was removed, and dimethyl sulfoxide was added. The optical
density was measured spectrophotometrically at 490 nm. Each experiment was
repeated at least three times.
For soft agar assay, cells were resuspended in DMEM containing 0.35%
agarose (ISC BioExpress, GenePure LE) and 10% FBS and seeded onto a
coating of 0.5% agarose in DMEM containing 10% FBS. Colonies were counted
2 to 4 weeks after preparation.

2.13

Tumor Growth in Nude Mice
Six-week-old female nude mice were used for experiments. All animal

studies were conducted in compliance with animal protocols approved by the
MD Anderson Institutional Animal Care and Use Committee. Before injection of
estrogen receptor-positive MCF7 cells, mice were implanted subcutaneously
with 0.72 mg of 17-β-estradiol 60-day release pellets (E2 pellet; Innovative
Research of America). Mice were injected in the mammary glands with 2 x 106
cells from various cell lines in 100 μl of phosphate-buffered saline. After 1 week,
tumors were measured every 3 days. Each cell line was tested in five different
animals. Volume was calculated as W2 x L x 0.52.
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CHAPTER 3 FUNCTION OF ZNF668 IN P53 AND TUMOR PROGRESS
REGULATION

3.1

ZNF668 localizes in the nucleus, accumulates in the nucleolus, and

interacts with NPM and nucleostemin
V5-tagged ZNF668 construct was induced to ectopically express ZNF668
protein in different breast epithelial cell lines, including MCF7 and MCF10A and
human mammary epithelial cells (HMECs). Western blotting analysis revealed a
70- to 80-kD V5-tagged band in all ZNF668-overexpressing cell lines. Through
motif analysis, two consensus nuclear localization sequences (R/K-R/K-X-R/K)
were detected in the N-terminal of ZNF668 protein (Figure 4), suggesting that
ZNF668 is a nuclear protein.

Figure 4. Sequence alignment of ZNF668 in different species. Boxed areas
correspond to the consensus nuclear localization sequence. NPM (B23) and NS
served as positive controls showing the consensus nuclear localization
sequence in well-known nuclear proteins.
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A rabbit polyclonal antibody was raised against a GST-ZNF668 fusion
protein (aa 183-483) and used for Western blotting analysis. This ZNF668
antibody also detected a band between 70 and 80 kD with its expression
enriched in the nuclear fraction (Figure 5). The specificity of our ZNF668
antibody was verified by small interfering RNA (siRNA) knockdown as well as
overexpression of V5-tagged ZNF668 (data not shown).

Figure 5. ZNF668 localizes predominantly in the nucleus. U2OS cells, HMECs,
and MCF7 cells were lysed in RIPA buffer or nuclear extraction buffer. Lamin
A/C and α-tubulin served as nuclear and cytoplasmic loading markers,
respectively.

Immunofluorescence analysis revealed specific nuclear staining for
ZNF668 with strong signals in one or more nucleolus-like nodular structures in
both MCF7 and MDA-MB-468 cells (Figure 6, upper two rows). The specificity of
the staining pattern was supported by V5 antibody staining in MCF7 cells and
HMECs with overexpression of V5-tagged ZNF668 (Figure 6, lower two rows),
and the nucleolar localization of ZNF668 was confirmed by ZNF668’s
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colocalization with two known nucleolar proteins, nucleostemin (NS) and NPM
(Figure 6).

Figure 6. ZNF668 accumulates in the nucleolus. Upper panel: MCF7 and MDAMB-468 cells were stained with antibodies against ZNF668 (red) and NS
(green). Lower panel: Ectopic V5-tagged ZNF668 was induced in MCF7 cells
and HMECs by doxycycline treatment. Cells were stained with V5 (green) and
NPM (red). Nuclei were visualized with DAPI (blue). Scale bars: 20 µm.

To systematically identify proteins involved in ZNF668 function, we
carried out immunoaffinity purification followed by mass spectrometry. We found
that NPM was a major ZNF668-associated protein (Figure 3). To validate the
mass spectrometry result, we performed immunoprecipitation/Western blotting
analysis and found that ZNF668 co-precipitated with NPM and NS (Figure 7A).
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The interaction between ZNF668 and NPM was further confirmed by reciprocal
immunoprecipitation using ZNF668 or NPM antibody (Figure 7B). These results
were consistent with results on immunofluorescent staining (Figure 6) and
strongly suggested that ZNF668 localizes in the nucleus, accumulates in the
nucleolus, and interacts with nucleolar proteins.

Figure 7. ZNF668 associates with NPM and NS. (A) U2OS cells were
transfected with empty vector or Flag-ZNF668; 48 h later, cells lysates (3 mg)
were immunoprecipitated and immunoblotted with antibodies against the
indicated molecules. (B) Endogenous association between ZNF668 and NPM.
Cell lysates from MCF7 cells were immunoprecipitated with anti-ZNF668, antiNPM, or preimmune IgG and immunoblotted with anti-ZNF668 or anti-NPM
antibody.
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3.2

ZNF668 interacts with MDM2 and p53
It has been shown that NPM and NS bind to and regulate the protein

stability and function of p53 (Colombo et al., 2002; Tsai and McKay 2002; Kurki
et

al.,

2004;

Ma

and

Pederson

2007).

Therefore,

we

performed

immunoprecipitation/Western blotting analysis to test whether ZNF668 also
interacted with p53. We found that ZNF668 interacted with p53 when ZNF668
was ectopically expressed in U2OS human osteosarcoma cells (Figure 8A and
B). Interestingly, ZNF668 also interacted with the negative regulator of p53,
MDM2 (Figure 8A and B).

Figure 8. ZNF668 interacts with MDM2 and p53. (A) ZNF668 associates with
MDM2 and p53 in vivo. U2OS cells were transfected with empty vector or FlagZNF668; 48 h later, cells lysates (3 mg) were immunoprecipitated and
immunoblotted with antibodies against the indicated molecules. (B) Ectopically
expressed p53 associates with ZNF668. U2OS cells were transfected with
empty vector or Flag-p53; reciprocally, cells were transfected with empty vector
or Flag-ZNF668. Forty-eight hours after transfection, cells lysates (3 mg) were
immunoprecipitated with M2-Flag conjugated beads and immunoblotted with
antibodies against the indicated molecules.
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The interactions between ZNF668, p53, and MDM2 were further
confirmed by reciprocal immunoprecipitation using ZNF668, p53, and MDM2
antibodies (Figure 9A), supporting the physical interactions among these three
proteins in cells. In vitro GST-protein binding assay also confirmed the
interactions among these three proteins (Figure 9B).

Figure 9. Endogenous ZNF668 interacts with MDM2 and p53. (A) Endogenous
ZNF668 associates with p53 and MDM2. Cellular lysates of MCF10A cells were
prepared by lysing the cells with RIPA buffer; immunoprecipitated with antiZNF668, anti-p53, anti-MDM2, or preimmune IgG; and immunoblotted with
antibodies against the indicated molecules. (B) In vitro interaction between
ZNF668, MDM2, and p53. GST-MDM2 and GST-p53 constructs were cleaved
using a thrombin cleavage capture kit. Cleaved MDM2 or p53 was mixed with
GST-ZNF668 in the binding buffer and incubated overnight at 4°C. Glutathione
beads were added into the reaction and incubated for 2 h at 4°C; this was
followed by extensive washing and analysis of the protein complexes by
Western blotting for the indicated molecules.
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To map the binding domain on ZNF668, we expressed FLAG-tagged
wild-type ZNF668 and ZNF668 mutants lacking different parts of amino acid
sequences in U2OS cells (Figure 10A). We found that both MDM2 and p53
could be co-precipitated with wild-type ZNF668, but their binding to ZNF668 with
N-terminal deletions was much weaker than their binding to ZNF668 with Cterminal deletions (Figure 10B). Regions aa84-aa190 and aa268-aa367 were
particularly important for the interaction between MDM2 and ZNF668: when
these two regions were deleted, the MDM2-ZNF668 interaction was abolished.
Interestingly, these two regions were also important for the interaction between
p53 and ZNF668. Notably, immunofluorescent staining showed that the ZNF668
deletions lacking regions aa84-aa190 and aa268-aa367 were localized
exclusively outside the nucleolar region, indicating that these two regions
contain the nucleolar localization signals for ZNF668 (Figure 10C). These results
identified the interaction domain of ZNF668 required for the interaction with
MDM2 and p53 and indicated the importance of the nucleolar localization of
ZNF668 for its interactions with MDM2 and p53.
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Figure 10. The interaction domain of ZNF668 with MDM2 and p53. (A) Summary
of the binding of ZNF668 deletions with MDM2 and p53. (B) Mapping of the
MDM2 and p53 binding domains of ZNF668. FLAG-tagged wild-type ZNF668
and deletion mutants of human ZNF668 were constructed and individually
transfected into U2OS cells. After 2 days, the cells lysates (3 mg) were
immunoprecipitated with M2-FLAG agarose beads and immunoblotted with
antibodies against the indicated molecules. (C) Immunofluorescent staining of
FLAG-tagged ZNF668 deletions. U2OS cells were overexpressed with FLAGZNF668 deletions and stained with antibodies against FLAG (green) and NPM
(red).

Conversely, we also sought to map the MDM2 domains that are required
for ZNF668 binding. We expressed MDM2 deletion proteins in U2OS cells that
constantly expressed FLAG-ZNF668. MDM2 has been shown to bind to p53
through the N-terminal domain (Kubbutat et al., 1999). Although FLAG-tagged
ZNF668 was co-precipitated with wild-type MDM2, an MDM2 protein carrying a
p53 binding domain deletion (MDM2 Δ58-89), and an MDM2 protein carrying a
C-terminal RING finger deletion (MDM2 Δ9), the interaction between ZNF668
and an MDM2 protein with the central region deleted (MDM2 Δ222-437) was
defective (Figure 11A, B and C). In contrast, we confirmed that p53 could form a
complex with wild-type MDM2, MDM2 Δ9, and MDM2 Δ222–437, but not MDM2
Δ58-89 (Figure 11C). These results indicated that p53 and ZNF668 bound to
different regions on MDM2. Further analysis of mutations within the central
region of MDM2 showed that deletion of aa212-aa296 significantly reduced the
binding between ZNF668 and MDM2, although deletion of aa295-aa417 did not
prevent their interaction (Figure 11B). Interestingly, a similar region of MDM2 is
required for binding to ARF and ribosomal protein L11, suggesting a common
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mechanism by which different molecules modulate the function of MDM2
(Bothner et al., 2001; Lohrum et al., 2003).

Figure 11. ZNF668 interacts with MDM2 in the central region. (A) Cartoon of the
MDM2 protein, indicating the position of principal domains and summarizing the
ZNF668 binding patterns. NLS: nuclear localization signal; NES: nuclear export
signal; NoLS: nucleolar localization signal. (B) Mapping of the MDM2 binding
domain of ZNF668. U2OS cells with constant Flag-ZNF668 overexpression were
transfected with the indicated MDM2 deletion mutants. Twenty-four hours after
transfection, the cells were lysed and immunoprecipitated with M2-Flag
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conjugated beads. Associated MDM2 protein was detected by Western blotting.
(C) Mapping of the MDM2 binding domain for p53 and ZNF668. U2OS cells with
constant Flag-ZNF668 overexpression were transfected with the indicated
MDM2 deletion proteins. Twenty-four hours after transfection, the cells were
lysed and immunoprecipitated using M2-Flag beads or p53 antibody with protein
A/G agarose beads. Associated MDM2 protein was detected by Western
blotting.

3.3

ZNF668 regulates p53 stability and activity
Since ZNF668 binds to MDM2 and p53, we next sought to determine

whether there is a causal relationship between ZNF668 status and p53 protein
levels. As shown in Figure 12A, when FLAG-tagged ZNF668 was ectopically
expressed in U2OS cells, we found increased p53 protein level as well as
increased level of the p53 downstream target p21. p53 mRNA levels were not
affected suggesting the effects were not on transcription or RNA stability.
Increased p53 protein expression was also seen when we overexpressed
ZNF668 in MCF7 cells and HMECs (Figure 12B).

Figure 12. ZNF668 regulates p53 stability and activity. (A) ZNF668 positively
regulates p53 protein expression without affecting p53 mRNA levels. U2OS cells
were transfected with empty vector or Flag-ZNF668, and cell lysates were
harvested and immunoblotted with antibodies against p53 and p21 (left panel) or
subjected to RT-PCR of p53 (right panel). (B) ZNF668 positively regulates p53
protein expression in different cell lines. ZNF668 was overexpressed in U2OS
and MCF7 cells and HMECs. Cell lysates were harvested and analyzed.
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To determine whether the increase in the p53 level was regulated at the
posttranslational level, we treated U2OS cells with cycloheximide to block de
novo protein synthesis. In these cells, overexpression of ZNF668 increased the
half-life of p53 protein from 1 h to more than 2 h (Figure 13A and B), suggesting
a role of ZNF668 in stabilizing p53 protein. Inversely, knockdown of ZNF668 with
siRNA in MCF7 cells resulted in a decrease of the p53 protein half-life from 2 h
to 30 minutes (Figure 13C).

Figure 13. ZNF668 regulates p53 protein stability. (A) U2OS cells were
transfected with empty vector or Flag-ZNF668. Cells were treated with
cycloheximide (CHX) for the indicated times, and cell lysates were harvested
and immunoblotted with antibodies against the indicated molecules. (B)
Quantification (mean of three experiments) of p53 protein levels in control and
ZNF668-overexpressing U2OS cells. (C) MCF7 cells were transfected with
control or ZNF668 siRNA. Cells were treated with CHX for the indicated times,
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and cell lysates were harvested and immunoblotted with antibodies against the
indicated molecules. Right panel: Quantification of p53 protein levels in control
and ZNF668-knockdown MCF7 cells.

To test whether ZNF668 regulates p53 activity, we transfected MCF10A,
MCF7, and U2OS cells with siRNA targeting ZNF668 and then treated the cells
with UV radiation (50 J/m2) or γ radiation (10 Gy). Cell lysates were harvested 2
h later, and the changes in ZNF668 and p53 were analyzed. In U2OS cells,
depletion of ZNF668 significantly reduced both stress-induced levels of p53 and
p53 basal levels (Figure 14A). Similar results were observed in MCF10A and
MCF7 cells (Figures 14B and C). The reduction in the level of p53 in response to
DNA damage was paralleled by a reduction in phosphorylation of Ser15 of p53
(Figure 14A), a marker of stress-induced p53 activation. Furthermore, we
observed a significant reduction in the expression of the p53 transcriptional
target p21 (Figure 14D). These results demonstrated that in ZNF668-knockdown
cells, the overall activation status of p53 and p53 downstream response after
DNA damage is impaired.
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Figure 14.
stabilization
transfected
treated with

ZNF668 regulates both the maintenance and stress-induced
of p53. (A) U2OS cells, (B) MCF10A cells and (C) MCF7 were
with siRNAs targeting ZNF668, and the knockdown cells were
UV radiation (50 J/m2) or γ radiation (IR; 10 Gy). Cell lysates were
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harvested 2 h later and immunoblotted with antibodies against the indicated
molecules. (D) ZNF668 regulates p53-downstream p21 expression. U2OS cells
were transfected with siRNAs targeting ZNF668, and the knockdown cells were
treated with γ radiation (IR; 10 Gy). Cell lysates were harvested 24 h later and
immunoblotted with antibodies against the indicated molecules.

Since ZNF668 has been shown to be mutated in breast cancer, we next
tested whether ZNF668 with mutations found in patient samples has the effect of
ZNF668 on p53 activity. FLAG-tagged ZNF668 vectors that harbored mutations
found in patient tumor samples were constructed through site-directed
mutagenesis and expressed in U2OS cells. Importantly, we found that mutant
ZNF668 could not stabilize p53 as efficiently as wild-type ZNF668 (Figure 15A).
We also tested whether wild-type and mutant ZNF668 were similar in terms of
regulating p53-dependent transcriptional activity. Analysis of p53 function using
a p53-luciferase reporter showed that the ability of ZNF668 mutants to activate
p53 was impaired compared to that of wild-type ZNF668 (Figure 15B). These
results indicated that ZNF668 mutations in patients may lead to impaired p53
activation, similarly to how p53 mutations can lead to impaired p53 activation.
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Figure 15. Mutant ZNF668 did not stabilize p53 as much as did wild-type
ZNF668. (A) U2OS cells were transfected with wild-type or mutant Flag-tagged
ZNF668. Forty-eight hours later, cell lysates were harvested and immunoblotted
with antibodies against the indicated molecules. (B) Luciferase assay in U2OS
cells transfected as indicated. Results represent the mean ± SD of three
experiments.

3.4

ZNF668 facilitates p53 stabilization by disrupting MDM2-mediated

ubiquitination and degradation
To determine whether ZNF668 regulates p53 protein stability through the
MDM2-mediated proteasome pathway, we first tested whether ZNF668 could
counteract the effect of MDM2 on p53. p53, MDM2, and ZNF668 were
coexpressed in U2OS cells. MDM2 significantly decreased the p53 protein level,
which could be restored, at least in part, by simultaneous expression of ZNF668
(Figure 16).
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Figure 16. ZNF668 partially restores p53 protein level when ZNF668 is coexpressed with MDM2. U2OS cells were transfected with p53 (0.05 μg), MDM2
(1 μg), and ZNF668 (0~1 μg). Cell lysates were harvested 48 h later and
immunoblotted with antibodies against the indicated molecules.

To test whether ZNF668 affects the interaction between MDM2 and p53,
we performed an in vitro binding assay. Purified GST-ZNF668, MDM2, and p53
proteins were mixed and pulled down with MDM2 antibody. We found that
addition of purified ZNF668 protein decreased MDM2-p53 binding in a dosedependent manner (Figure 17). These data indicated that ZNF668 disrupts the
interaction between MDM2 and p53.
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Figure 17. The presence of ZNF668 decreases the interaction between MDM2
and p53. Purified MDM2 and p53 were mixed in in vitro binding buffer, and GSTZNF668 was added into the reaction at different GST-ZNF668:MDM2 ratios (0:1,
2:1, 4:1, and 8:1). Two hours later, the protein complex was immunoprecipitated
with MDM2 antibody and immunoblotted with antibodies against the indicated
molecules.

The presence of nutlin, which inhibits MDM2-p53 interaction, stabilizes
and activates p53 (Vassilev et al., 2004; Colaluca et al., 2008). We found that
nutlin treatment of ZNF668-knockdown cells reversed the effect of ZNF668
knockdown on DNA damage-induced p53 activation (Figure 18). These results
further supported the MDM2-p53 interaction as the key target of by which
ZNF668 induces p53 stabilization.
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Figure 18. Nutlin restores ZNF668 knockdown effects on p53 response to DNA
damage. U2OS cells were transfected with siRNA duplexes targeting ZNF668,
and the ZNF668-knockdown cells were pretreated with or without nutlin. Two
hours later, cells were treated with UV radiation (50 J/m2) or γ radiation (IR; 10
Gy). Cell lysates were harvested 2 h later and immunoblotted with antibodies
against the indicated molecules.

3.5

MDM2 regulates p53 protein turnover through its E3 activity
To test whether ZNF668 blocks MDM2-mediated p53 ubiquitination and

degradation, cells were treated with the proteasome inhibitor MG132. As
expected, MG132 treatment abolished the effect of ZNF668 on p53 level (Figure
19A, left). Moreover, we detected decreased ubiquitination of p53 when ZNF668
was overexpressed (Figure 19A, right), suggesting a role of ZNF668 in
counteracting MDM2-mediated p53-ubiquitination. Interestingly, we also found
that ZNF668 facilitated MDM2 autoubiquitination (Figure 19B). This observation
was consistent with previous findings that L11 differentially regulates MDM2 and
p53 ubiquitination (Dai et al., 2006). We speculate that in addition to directly
blocking MDM2-p53 interaction (Figure 17), ZNF668 might also alter MDM2’s
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function by inducing autoubiquitination of MDM2 molecules. The dysregulated
ubiquitination of MDM2 might further facilitate the stabilization of p53 by altering
MDM2 E3 ligase activity or MDM2’s binding affinity for its substrates.

Figure 19. ZNF668 affects p53 and MDM2 ubiquitination. (A) ZNF668 decreases
endogenous p53 ubiquitination. U2OS cells were transfected with Flag-ZNF668
and treated with or without 10 μM MG132 for 6 h. Cell lysates were harvested
and analyzed. p53 levels were normalized by loading proportionally different
amounts of cell extracts. Cell lysates were immunoprecipitated with p53 antibody
and immunoblotted as indicated. (B) ZNF668 increases endogenous MDM2
ubiquitination. U2OS cells were transfected with Flag-ZNF668 and treated with
or without 10 μM MG132 for 6 h. Cell lysates were harvested and analyzed. Cell
lysates were immunoprecipitated with MDM2 antibody and immunoblotted as
indicated.
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3.6

ZNF668 suppresses tumorigenicity of human breast cancer cells
Since we found that ZNF668 regulates the stability of p53 protein, we

posited that ZNF668 might itself function as a tumor suppressor gene. To test
this possibility, we first examined the proliferation of cells ectopically expressing
ZNF668. Overexpression of ZNF668 repressed proliferation of MCF7 cells
(Figure 20A) and their ability to grow in soft agar (Figure 20B). In contrast,
knockdown of ZNF668 increased soft agar colony formation in nontumorigenic
MCF10A cells (Figure 20B).
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Figure 20. ZNF668 suppresses proliferation and transformation of human breast
cancer cells. (A) Expression of ZNF668 reduces the proliferation of MCF7 cells.
Control or ZNF668-overexpressing MCF7 cells were seeded in a 96-well plate at
5×103 cells per well. Cell proliferation was measured by MTT assay for 4 days.
Results represent the mean ± SD of three independent experiments. (B)
Expression of ZNF668 reduces the cell transformation of MCF7 cells.
Knockdown of ZNF668 increases the transformation of MCF10A cells. ZNF668expressing MCF7 cells or ZNF668-knockdown MCF10A cells were seeded in
0.35% agarose gel at 1×104 or 5×103 cells per plate. Viable colonies of MCF7 or
MCF10A clones in three plates were counted; all soft agar assays were
performed in triplicate. Results represent the mean ± SD of three independent
experiments.

Given that ZNF668 effectively suppressed in vitro cellular transformation,
we next tested whether ZNF668 suppressed tumorigenicity in vivo. Mice were
injected in the mammary glands with ZNF668-overexpressing or vector-control
MCF7 cells and monitored weekly for tumor formation. By week 8, all 10 mice
injected with ZNF668-overexpressing clones remained tumor free, whereas all
five of the control mice had developed tumors (Figure 21), indicating the ability
of ZNF668 to suppress tumorigenicity in vivo.
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Figure 21. ZNF668 suppresses tumor growth. ZNF668-overexpressing or vectorcontrol MCF7 cells were injected into the mammary glands of nude mice (5×106
cells per mouse), and tumor volumes were measured every 2 days. Results
represent the mean ± SD of three independent experiments.

3.7

ZNF668 suppresses tumorigenicity in both p53-dependent and

independent-manners
To determine whether p53 is the only target mediating ZNF668’s activity
in suppressing cellular transformation, we also performed in vitro cell
proliferation and transformation assays using MCF7-p53-knockdown cells. Both
MCF7-control and MCF7-p53-knockdown cells were transfected with FLAGtagged ZNF668, and cells were selected with G418 for 10 days. Overexpression
of ZNF668 was confirmed by Western blotting analysis (Figure 22A). ZNF668
suppressed the proliferation and transformation phenotype (Figure 22B and C)
of MCF7-p53-knockdown cells, but to a lesser extent than it suppressed the
proliferation and transformation phenotype of MCF7-control cells, indicating that
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ZNF668 could suppress cell transformation through both p53-dependent and
p53-independent pathways.

Figure 22. ZNF668 suppresses transformation phenotype of human breast
cancer cells partially through p53. (A) Expression of Flag-ZNF668 in MCF7
control and MCF7-p53-knockdown (KD) cells. Cells were transfected with FlagZNF668. Two days later, cells were split and selected with G418 for another 10
days. Cell lysates were harvested and immunoblotted with antibodies against
the indicated molecules. (B) Expression of ZNF668 reduces the proliferation of
both MCF7 control and MCF7-p53-knockdown cells. Cells were transfected with
Flag-ZNF668 and seeded in a 96-well plate at 5×103 cells per well. Cell
proliferation was measured by MTT assay for 4 days. The growth rates of cells
were calculated. Results represent the mean ± SD of three independent
experiments. (C) ZNF668 suppresses cell transformation in both MCF7 control
and MCF7-p53-knockdown cells. Cells were transfected with Flag-ZNF668 and
seeded in 0.35% agarose gel at 5×103 cells per plate. Left: viable colonies in
three plates were counted. Right: the colony formation rate was calculated; all
soft agar assays were performed in triplicate. Results represent the mean ± SD
of three independent experiments. Student’s t-test.
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3.8

Discussion
Our findings identify ZNF668 as a novel nucleolar protein that interacts

with known nucleolar proteins NPM and NS. Recent studies have shown that the
function of nucleolar proteins is not limited to participating in ribosomal
biogenesis. Indeed, the nucleolus appears to be the site for convergence of the
p53 pathway through regulation of different nucleolar proteins under various
types of cellular stress (Kamijo et al., 1998; Colombo et al., 2002; Tsai and
McKay 2002; Lohrum et al., 2003; Dai et al., 2006). Thus, the nucleolar
localization of ZNF668 and its interaction with known nucleolar proteins
suggested a potential role of ZNF668 in p53 regulation.
By forward and reverse genetic approaches, we clearly demonstrated a
critical role of ZNF668 in p53 protein stabilization through inhibition of the p53
negative regulator, MDM2. Our findings further suggest that ZNF668 regulates
MDM2 through a direct interaction between ZNF668 and MDM2-p53 complex
since ZNF668 interacted with MDM2 and p53 in vivo and in vitro and since
ZNF668 interfered with the MDM2-p53 interaction. It has been shown that
physical interaction between MDM2 and p53 is a prerequisite for MDM2 to
ubiquitinate p53 (Haupt et al., 1997; Kubbutat et al., 1997; Michael and Oren
2003). Therefore, our results strongly support alterations in direct protein-protein
interactions as a mechanism by which ZNF668 regulates p53 and MDM2mediated p53 ubiquitination in vivo. Our findings do not, however, exclude the
possibility that ZNF668 could also regulate p53 through other pathways. For
example, p53 can be regulated at the posttranslational level through
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modifications such as phosphorylation and acetylation. ZNF668 could serve as a
platform for assembly of complexes needed for p53 posttranslational
modifications in response to cellular stress and thereby promote p53 activation
and stabilization. Future experiments will be needed to determine whether other
mechanisms besides direct protein-protein interactions may also be involved in
ZNF668-mediated p53 regulation.
Recent reports indicate that the central acidic domain of MDM2 is
important for controlling p53 activity (Ma et al., 2006; Wallace et al., 2006).
Indeed, this domain was previously shown to be required for p53 ubiquitination
and degradation (Argentini et al., 2001; Meulmeester et al., 2003). We found in
the current study that deletion of residues 212-296 of MDM2 attenuated the
interaction between ZNF668 and MDM2, indicating a mechanism by which
ZNF668 could attenuate MDM2-mediated ubiquitination and degradation of p53.
Indeed, it has previously been suggested that the ubiquitination of p53 is a
stepwise process accompanied by a conformational alteration (Gu et al., 2001).
Therefore, it is possible that binding of ZNF668 to the central domain of MDM2
induces a conformational change in both MDM2 and p53 that suppresses the
ubiquitination of p53 but facilitates the autoubiquitination of MDM2 (Figure 23).
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Figure 23. Schematic model of how ZNF668 interaction with MDM2 protects p53
from ubiquitin-mediated degradation. p53 is maintained at a low basal level in
normal cells by MDM2-mediated degradation. When ZNF668 is present, it
associates with both p53 and MDM2 and prevents MDM2-mediated degradation
of p53 by disrupting the interaction between MDM2 and p53. The presence of
ZNF668 leads to an increase of MDM2 auto-ubiquitination and decrease of p53
ubiquitination, which stabilizes p53.

Balancing MDM2 autoubiquination and ubiquination of its substrates such
as p53 highly depends on the association between MDM2 with p53 (Stommel
and Wahl 2004; Ronai 2006). DNA-damage induced phosphorylation of MDM2
results its dissociation with modified p53 and leads to accelerated MDM2
autoubiquitination and consequently, p53 stabilization and activation (Stommel
and Wahl 2004). Our data indicated that ZNF668 could block the interaction
between MDM2 and p53 (Figure 17), thus facilitated MDM2 autoubiquitination
and p53 stabilization. Interestingly, it has been shown that L11 and ARF
(Xirodimas et al., 2001; Brignone et al., 2004; Dai et al., 2006; Ronai 2006) can
also facilitate autoubiquitination of MDM2 by preventing the recruitment of
ubiquitinated MDM2 to the proteasome, either through potential adaptor proteins
or by concealing MDM2 binding sites in the proteasome (Brignone et al., 2004;
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Ronai 2006), thus inhibiting the postubiquitination pathway. It is therefore
tempting to speculate that many p53 regulators, such as ARF and ZNF668,
stabilize p53 protein both by directly interfering with MDM2-p53 interaction and
by regulating MDM2 posttranslational modifications such as autoubiquitination to
alter MDM2 E3 ligase activity or binding affinity toward its substrates.
Our studies also identified ZNF668 as a potential tumor suppressor in
breast cancer. ZNF668 was previously identified as a highly mutated gene in
breast cancer. However, the implications of the mutation of ZNF668 in breast
cancer development are entirely unknown. Our studies strongly indicate p53 to
be an important target of ZNF668. Indeed, the two ZNF668 mutants that we
tested had impaired ability to stabilize p53 further support this notion. Of course,
we cannot rule out impacts of ZNF668 on proteins other than p53. Indeed, the
fact that ZNF668 also suppressed cell transformation in p53-mutated cells
(Figure 22), albeit to a lesser degree than in cells with wild-type p53, indicates
that ZNF668 can suppress cell transformation through both p53-dependent and
p53-independent pathways. In future studies, we will identify the p53independent ZNF668 targets and dissect the function of ZNF668 in both p53dependent and p53-independent pathways.
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PART II.

ROLE OF ZNF668 IN DNA REPAIR AND CHROMATIN

REMODELING

CHAPTER 4 INTRODUCTION

4.1

Tumor suppressor and DNA repair
Tumor suppressor genes have diverse functions. The role of tumor

suppressors in DNA damage response is well established. Many tumor
suppressors, such as ATM, BRCA1, BRCA2, NBS1, CHK2 and p53, are
involved in different steps of DNA damage response pathway, which leads to
checkpoint response, increased DNA repair or cell apoptosis (Liang et al., 2009).
Loss of the function of tumor suppressors leads to genetic instability, deficient
DNA repair or impaired damaged cell death and results in tumor formation. For
example, the tumor suppressor genes BRCA1 and BRCA2 play roles in DNA
damage repair (Venkitaraman et al., 2001). BRCA2 belongs to the tumor
suppressor gene family and the protein encoded by this gene is involved in the
repair of chromasomal damage with an important role in HR repair of DNA
double strand breaks (Venkitaraman et al., 2001). Understanding the role of
tumor suppressors in DNA damage response pathway provides an alternative
opportunity for improving disease detection and management.

4.2

DNA damage response pathways
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Cellular DNA is continuously exposed to various DNA damage signals
(Hoeijmakers et al., 2009). Endogenous signals including spontaneous DNA
alterations during replication, reactive oxygen species generated by cellular
metabolism activity and intercross between DNA bases. Exogenous signals
such as chemicals, UV radiation and ionizing radiation can cause different types
of DNA lesions.
DNA damage response is a highly conserved but complicated process
with multiple steps including the initial recognition and signaling of DNA lesions,
the access of repair proteins to the damaged DNA and the restoration of the
chromatin to its original state (Harper et al., 2007; Rouse et al., 2002). Although
there are different types of DNA repair in response to different classes of DNA
lesions, DNA damage responses usually occur by a common general process
(Figure 24). Right after the DNA damage, DNA damage sensors detect the
damage and recruit transducer kinases such as ATM/ATR/DNA-PK and
mediators such as MDC1 to the damage sites. The kinases will activate
downstream effectors with the coordination of mediators. Mediators mediate the
signal from the transducer kinases to the effectors. Effectors execute the DNA
damage response, which includes activation of cell cycle checkpoints, repair of
the damage, transcriptional regulation and activation of apoptosis if the damage
is too severe to be repaired (Bartkova, 2007).
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Figure 24. A common model for the DNA damage response. The presence of a
lesion in the DNA, which can lead to replication stalling, is recognized by various
sensor proteins. These sensors initiate signaling pathways that have an impact
on a wide variety of cellular processes. (Stephen P. Jackson & Jiri Bartek, 2009)

4.3

DNA repair pathways
To preserve its genomic integrity, cells need to develop different types of

repair pathways to fix the various types of DNA damage. For example, baseexcision repair (BER) is important for the repair of DNA alterations caused by
chemicals (Jiricny et al.,2006); mismatch repair (MMR) can replace the
misrepaired DNA bases with correct bases; nucleotide excision repair (NER)
repairs more complex lesions, such as pyrimidine dimers and intrastrand
crosslinks; single-strand break repair (SSBR) repairs single strand breaks
caused by UV irradiation; double strand breaks (DSBs) are mainly repaired by
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homologous recombination (HR) and nonhomologous endjoining (NHEJ)
(Caldecott, 2008; West, 2003).
For DNA double strand breaks, HR uses the undamaged sister
chromatids as template to accurately restore the break. In contrast, NHEJ
repairs the break by direct ligation of the two broken ends, which can result in
inaccurate relegation of the breaks and cause DNA deletions. Cells activate
different repair pathway in co-ordinance with specific cell cycle phase (Figure
25) (Branzei et al., 2008; Mandal et al., 2010).

Figure 25. DNA double strand break repair during cell cycle. In G1, double
strand breaks are recognized by the KU dimer to provide a scaffold and recruit
the repair proteins to perform NHEJ repair. In S and G2 cells, DNA lesions are
detected and processed by the MRE11–RAD50–NBS1 (MRN) complex. This
leads to recruitment and activation of ataxia-telangiectasia mutated (ATM)
signalling pathway and leads to transient cell cycle arrest for DNA repair.
Replication blocks during S phase activate ataxia-telangiectasia- and RAD3related (ATR) activation and lead to cell cycle arrest (Mandal et al., 2010). HR
repair is the major repair pathway during G2/S phase.

4.4

Chromatin dynamics and gene regulation
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In eukaryotic cells, genomic DNA is packed with histones to form the
nucleosomes, which are further packaged into a condensed chromatin structure.
Nucleosomes are comprised of 147 bp of DNA wrapped around a heterooctamer of histones H2A, H2B, H3, and H4 (Khorasanizadeh, 2004). Generally,
the condensed chromatin structure will suppress cellular processes that involve
DNA transactions such as DNA replication, gene transcription and DNA double
strand break repair (Felsenfeld et al., 2003).
Gene transcription initiation involves the opening of chromatin structure at
the promoter region to allow access for transcription factors to bind DNA
sequences (Wollffe 1998). In order to overcome the chromatin barrier, cells
have developed several pathways to relax the chromatin structure. The ATPdependent chromatin remodeling complexes utilize the energy from ATP
hydrolysis to displace nucleosomes and induce conformational changes in
chromatin (Lusser et al., 2002; Peterson et al., 2002; Flaus et al., 2004). The
posttranslational modifications of the core histones, such as phosphorylation,
methylation, ubiquitination and acetylation (Jenuwein et al., 2001; Turner, 2002;
Kouzarides et al., 2007) have emerged as another important mechanism by
which cells regulate the structure and accessibility of chromatin. Moreover, cells
alter the composition of nucleosomes through the incorporation of histone
variants that can directly or indirectly alter the accessibility of DNA within
chromatin (Kamakaka et al., 2005; Henikoff et al., 2005).

4.5

Chromatin dynamics and DNA repair
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The chromatin structure also has an impact on the DNA damage
response because in the DNA damage pathway, the condensed chromatin
structure blocks the DNA repair machinery to access the damaged chromosomal
DNA lesions. The chromatin structure is modulated by several mechanisms in
response to DNA damage.
ATP-dependent chromatin remodeling complexes regulate the chromatin
structure in response to DNA damage signal. With the DNA damage signal,
ATP-dependent chromatin remodelers such as INO80, SWR1 Swi2-family
proteins and SWI/SNF chromatin remodeling factors are recruited to the double
strand breaks (Narlikar et al. 2002; Morrison et al., 2004; van Attikum et al.,
2004; Shim et al., 2005; Chai et al., 2005). These remodelers are responsible for
efficient initiation of DNA damage response including the induction of histone
phosphorylation.

They

are

also

responsible

for

the

followed

histone

ubiquitination, nucleosome reassemble and the exchange of histones in the
DNA damage breaks.
Combinations of the posttranslational modifications in the core histones
will form so-called “histone code” to regulate different types of cellular process
such as gene regulation, DNA repair and chromatin condensation (Strahl et al.,
2000). The posttranslational modifications of the core histones can regulate the
structure and accessibility of chromatin. The amino- and carboxy-terminal tails
of histones are the regions that frequently be modified because of their location
on the chromatin surface. In addition to histone modifications, there are different
histone variants that consist of different sequence and play different roles from
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canonical histones. For example, one of the major H2A variants, H2AX differs
from H2A at various amino acid residues along the entire protein and in its Cterminal extensions. H2AX is phosphorylated in response to the introduction of
DNA double-strand breaks, and the phosphorylated H2AX (γ-H2AX) participates
in foci formation at sites of DNA damage and plays an important role in the
recognition and signaling of DNA Damage. The phosphorylation of H2AX is
mediated by ATM/DNA-PK/ATR. ATM and DNA-PK majorly function after
ionizing radiation (IR), whereas ATR responds to replication stress and UV
irradiation (Rogakou et al., 1998; Stiff et al., 2004; Czornak et al., 2008;
Cimprich et al., 2008). Studies have shown that phosphorylated-H2AX (γ-H2AX)
serves as a platform to recruit and retain DNA repair factors to the DNA damage
sites without affecting chromatin organization (Celeste et al., 2003). After DNA
damage, the γ-H2AX is expanded around the double strand break region and
provides docking sites for other DNA damage and repair proteins such as
53BP1 and BRCA1.
The re-open of condensed chromatin structure for efficient DNA repair
involves induced histone acetylation at the DSB sites. After the incorporation of
γ-H2AX, other core histones such as H2A, H3 and H4 are modified by
acetylation and contribute to the destabilization of the nucleosome and the
opening of chromatin. Other histone modifications such as ubiquitylation and
sumoylation also have roles in histone exchange and the recruitment of the
chromatin remodeling complexes (Attikum et al., 2009).

53

After repair has been completed, γ-H2AX is eliminated from the chromatin
surrounding the repaired DSB, by either replacement with H2AZ variant
(Mizuguchi et al., 2004) or dephosphorylation by phosphatases such as hPP2A,
hPP4C, hPP6 and hWip1 (Chowdhury et al., 2005; Chowdhury et al., 2008;
Macurek et al., 2010; Douglas et al., 2010).

4.6

Histone acetylation and its role in transcription regulation
Among all the posttranslational modifications of histones, histone

acetylation by histone acetyltransferase (HAT) complexes has been implicated
in both transcriptional regulation and DNA damage repair.
HAT can catalyze the transfer of an acetyl group from acetyl-CoA to the
lysine amino groups on the N-terminal tails of histones. In actively transcribed
regions of chromatin histones tend to be hyperacetylated, whereas in
transcriptionally silent regions histones are hypoacetylated. Histone acetylation
can neutralize histone charge and weaken DNA-histone interaction. The acetyllysines on histone tails can provide recognition sites for transcription factors
involved in either the activation or repression of gene expression. For example,
lysine acetylation provides a stable epigenetic mark on chromatin for SWI/SNF
and RSC chromatin remodeling complex or HAT complexes to dock and in turn
regulate gene expression (Hassan et al., 2002).
In addition, other covalent modification of histones, which is called as
histone code, will provide an epigenetic marker for gene expression (Strahl et
al., 2000). The complexity of the histone code also influences recruitment of
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HAT to promoters. For example, phosphorylation of histone H3 serine 10 can
enhance the targeting of Gcn5 HAT to the INO1 promoter in yeast (Lo et al.,
2001). In mammals, methylation of H3 lysine 9 inhibits HAT targeting and
promoter acetylation (Rea et al., 2000). All of these histone modifications will
coordinately provide a unique signal for specific gene activation or suppression.

4.7

Histone acetylation and DNA repair
Recent studies have implicated the role of chromatin acetylation by HAT

complexes in DNA-damage detection and DNA repair (Ikura et al., 2000;
Carrozza et al., 2003; Murr et al., 2006). For example, Tip60 is one of the HATs
that acetylate H2A and its variant H2AX on lysine 5 (K5). In drosophila, Tip60’s
activity on H2Av acetylation is important for histone variant H2AZ exchange with
phosphorylated-H2AX, which is important for DNA repair (Kusch et al., 2004).
Acetylation of H2AX (Kusch et al., 2004; Downs et al., 2004) and histone H4
(Murr et al,. 2006; Bird et al., 2002; Downs et al., 2004) is required for the
formation of open chromatin structures at DSBs and is critical for the access of
the DNA repair machinery to DSBs (Murr et al., 2006; Bird et al., 2002; Kusch et
al., 2004; Jha et al., 2008). Recent studies also showed that H3 acetylation on
lysine 56 (K56) is required for the appropriate nucleosome assembly and
facilitates DNA double strand break repair (Li et al., 2008; Chen et al., 2008).
Therefore, the increased acetylation of histones at DNA lesions after DNA
damage can contribute to DNA double strand break repair by regulating histone
variant exchange, remodeling chromatin structure and recruiting DNA repair
proteins to the sites of DNA damage. However, the precise underlying
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mechanism mediating enzymes responsible for the histone modifications and
their recruitment to DNA lesions remains poorly understood.

4.8

Hypothesis and project goals
ZNF668 (zinc finger protein 668) was initially identified and validated as a

highly mutated gene in breast cancer (Sjoblom et al., 2006). Our preliminary
data showed that ZNF668 functions as a potential tumor suppressor and it is
involved in p53 regulation. Since tumor suppressors play an important role in
DNA damage response, we hypothesize that, as a novel tumor suppressor and
a key regulator of p53, ZNF668 might participate in DNA damage response.
In this part of the study, we aim to demonstrate the functional interaction
among ZNF668, histones, and chromatin. We study the role of ZNF668 as a
novel tumor suppressor gene in regulation of histone acetylation and chromatin
structure after DNA damage and reveal its mechanistic function in regulating
DNA damage repair.

CHAPTER 5 MATERIALS AND METHODS

5.1

Cell Culture and Transfection
U2OS cells were purchased from the American Type Culture Collection.

U2OS cells were maintained in McCoy's 5A medium (Cellgro) supplemented
with 10% fetal bovine serum (FBS) with glutamine, penicillin, and streptomycin.
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Cells were incubated at 37°C in a humidified incubator with 5% CO2 and
transfected with Fugene 6 (Roche), or Oligofectamine (Invitrogen).

5.2

Plasmids and small interfering RNAs (siRNAs)
To generate FLAG-ZNF668, full-length ZNF668 cDNA was amplified by

polymerase chain reaction (PCR) and subcloned into pCMV5-3 x FLAG vector
(Sigma). The siRNA-resistant ZNF668 was created from 3 x FLAG-ZNF668
using the QuickChange II Site-Directed Mutagenesis Kit (Stratagene). FLAGH2AX plasmid was a gift from Dr. Jiri Lukas. ZNF668 knockdown was achieved
by RNA interference using siRNA (Dharmacon). The ON-TARGETplus ZNF668
siRNA duplex and ON-TARGETplus SMARTpool ZNF668 siRNA mix were
purchased from Dharmacon Research, Inc. ON-TARGETplus nontargeting
siRNA was used as a control for the siRNA reactions. RNA duplexes or
SMARTpool (final concentration 100 nM) were transfected into the U2OS cells
using Oligofectmine according to the manufacturer’s protocol (Invitrogen). Cells
transfected with ZNF668 siRNA were incubated for 2 or 3 days. A decrease in
the respective protein levels was verified by Western blotting.

5.3

Antibodies and Reagents
Rabbit polyclonal anti-ZNF668 antibody (Proteintech Group, Inc.) was

generated as described in Chapter 2.3. Anti-FLAG M2-agarose affinity gel was
purchased from Sigma. RPA antibody was purchased from NeoMarkers.
Phospho-RPA32 (S4/S8) antibody was purchased from Bethyl. Rad51 was
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purchased from Calbiochem, ATM, phospho-H2AX were purchased from Cell
Signaling. Histone H2A (acetyl K5) antibody was from Abcam. Anti-Tip60 and
phospho-ATM
secondary

were

purchased

antibodies

were

from

Millipore.

purchased

from

Fluorochrome-conjugated

Jackson

ImmunoResearch

Laboratories. Cisplatin was purchased from Sigma. Sodium butyrate and
trichostatin were obtained from Sigma and used at 5 mM or 200 ng/mL
respectively.

5.4

Affinity purification of ZNF668 and H2AX protein complex
U2OS cells were transiently transfected with empty FLAG plasmid, FLAG-

ZNF668 or FLAG-H2AX plasmid. Forty-eight hours later, whole cellular extracts
were prepared with RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 10%
sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 1 mM sodium orthovanadate, and 1 mM NaF) and immunoprecipitated
with

anti-FLAG

immunocomplexes

M2
were

affinity
eluted

gel

(Sigma)
with

overnight.

3XFLAG

Bead-bound

peptide

(Sigma).

Immunocomplexes were separated by 7% or 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Protran
nitrocellulose membrane (Fisher Scientific). Membranes were blocked in Trisbuffered saline-0.1% Tween 20 (TBS-T)/5% (w/v) milk for 1 h at room
temperature and were then incubated with primary antibodies diluted in TBST/5% (w/v) milk for 2 h at room temperature or overnight at 4°C. Subsequently,
membranes were washed with TBS-T and incubated with horseradish
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peroxidase secondary antibody (1:5000) (Jackson ImmunoResearch) diluted in
TBS-T/5% skim milk. Membranes were washed in TBS-T, and bound antibody
was detected by enhanced chemiluminescence (GE Healthcare).

5.5

Immunofluorescent Microscopy
For detection of DNA damage induced foci of p-RPA34, RPA34 and

Rad51, cells were treated with cytoskeleton and stripping buffer, fixed with 4%
paraformaldehyde and then permeabilized with 0.5% NP-40 and 1% Triton X100. The primary antibodies were as follows: mouse anti-RPA (1:1000), rabbit
anti-pRPA (1:1000) and rabbit anti-Rad51 (1:500). Primary antibodies were
incubated for 2h at room temperature (RT) and secondary antibodies donkey
anti-rabbit conjugated Alexa 594 and goat anti-rabbit conjugated Alexa 488 were
incubated for 1 h at RT. Slides were mounted in medium containing DAPI
(Vector laboratories, Burlingame, CA) and analyzed under a fluorescence
microscope. The number of foci per cell was scored for at least 50 cells per
sample. For chromatin remodeling, cells were incubated in the presence of
sodium butyrate (5 mM) after ultraviolet (UV) or ionized radiation (IR) exposure
before staining for DNA damage foci was performed.

5.6

Immunoblotting, chromatin fractionation and Immunoprecipitation
Cells were washed in phosphate-buffered saline and lysed in urea buffer

or modified RIPA buffer. For chromatin fractionation, cells were lysed in (10 mM
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.34 M sucrose, 10% Glycerol, 1
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mM dithiothreitol, and 0.1% Tirton X-100), and nuclear extracts were lysed in
buffer (3 mM EDTA, 0.2 mM EGTA and 1 mM dithiothreitol). After clarification,
cell pellets were resuspended in SDS sample buffer. For immunoprecipitation,
cells were lysed in RIPA buffer. After clarification, cell lyses were
immunoprecipitated

with

specific

antibodies

(RPA

or

ZNF668).

The

immunocomplexes were collected on Protein A/G plus-conjugated agarose
beads (Santa Cruz Biotechnology). Cellular lysates or immunocomplexes were
subjected to SDS-PAGE analysis.

5.7

Cell survival and proliferation assays
U2OS cells were transfected with ZNF668 siRNAs and 72 h after the

transfection, cells were plated at low density and irradiated with UV or IR. Cells
were incubated for 2–3 weeks to allow colonies to form. Colonies were detected
by staining with 2% methylene blue/50% ethanol. Colonies containing 50 or
more cells were counted. For proliferation assay, cells transfected with ZNF668
siRNAs were seeded in 96 well plates and treated with various doses of
cisplatin. 72 h after the treatment, MTT assay was performed to measure cell
viability.

5.8

HR repair analysis
U2OS cells containing a single copy of the HR repair reporter substrate

DR-GFP in a random locus were generated as previously described (Peng et al.,
2009). U2OS-DR-GFP cells were transfected with ZNF668 siRNA with or without

60

siRNA-resistant FLAG-ZNF668. 48 hours after transfection, cells were
transfected with pEGFP-C1 as for transfection efficiency control or pCBASce
plasmid for detection of HR repair efficiency. 48 hours later, GFP positive cells
were detected by flow cytometry analysis. Cellquest software (Becton Dickinson,
San Jose, CA) is used for the acquisition and analysis of FACS data. For
chromatin remodeling recovery experiments, cells were incubated for 16 hr in
sodium butyrate (5 mM) or trichostatin (200 ng/mL) to induce chromatin
remodeling before analysis by flow cytometry.

5.9

PCR analysis of I-SceI-induced DNA cutting
To assay the cutting efficiency of I-SceI in cells transfected with control or

ZNF668 siRNA, genomic DNA was extracted at different time points after I-SceI
transfection and adjusted to equal concentrations. Semi-quantitative PCR was
carried out using the primers around the DSB site (30 cycles). Beta-actin primers
(Applied biosystems) were used as an internal control (25 cycles).

5.10

Cell cycle analysis
Cells from HR repair analysis were fixed in 70% cold ethanol (-20°C)

overnight. After washing with cold phosphate-buffered saline (PBS), cells were
incubated in staining solution (40 μg/mL propidium iodide, 50 μg/mL RNAase A
and 0.05% Triton X-100). Cell cycle analysis was performed at the M. D.
Anderson Cancer Center Flow Cytometry Facility.
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CHAPTER

6

FUNCTION

OF

ZNF668

IN

DNA

REPAIR,

HISTONE

ACETYLATION AND CHROMATIN STRUCTURE REGULATION

6.1

ZNF668 depletion causes prolonged DNA damage after IR.
To understand the role of ZNF668 in DNA damage response, we first

measured cell survival following treatment with DNA damage agents. ZNF668
deficient cells showed an increased sensitivity to ionize irradiation and UV light
by clonogenic survival assays (Figure 26A). In a cell proliferation assay, ZNF668
knockdown cells were also sensitive to DNA cross-linking agent cisplatin in a
dose dependent manner (Figure 26B). These data indicate ZNF668 depletion
cells are sensitive to DNA damage. Therefore, ZNF668 is needed for cell
survival in response to a wide variety of DNA damaging agents.

Figure 26. ZNF668 depletion impairs cell survival after DNA damage. (A)
ZNF668-depletion impaired cell survival in U2OS cells exposed to UV or IR
radiation. Control or ZNF668-depletion U2OS cells were seeded at low density
and treated with UV or IR. Viable cell colonies in three plates were counted. The
graphs represent the mean ± SD of three independent experiments. (B)
ZNF668-depletion impaired cell proliferation in cells exposed to DNA damage
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reagent (cisplatin). Control or ZNF668-depletion U2OS cells were seeded in a
96-well plate at 2×103 cells per well and treated with various doses of cisplatin.
Cell proliferation was measured by MTT assay after 3 days. Results represent
the mean ± SD of three independent experiments.

6.2

ZNF668 affects DNA damage repair.
Effective DNA repair of damaged DNA is essential to cell survival. To test

whether ZNF668 plays a role in DNA repair, we measured DNA repair efficiency
in ZNF668 knockdown cells using the neutral comet assay that specifically
measures double-strand breaks (DSB). Although induction of DNA breaks was
similar in ZNF668-containing and ZNF668-deficient cells, ZNF668-deficient cells
exhibited a lower repair efficiency compared to control, thereby indicating that
ZNF668 depletion compromised the repair of DNA breaks (Figure 27).

Figure 27. ZNF668-depletion impaires DNA repair. Comet analyses at the
indicated time points after exposure of U2OS cells transfected with control
siRNA, ZNF668 siRNA #1 or ZNF668 siRNA #2 to ionizing radiation (IR). (Left)
Representative images. (Right) Quantitative analysis of three independent
experiments and representative western blot analyses showing the knockdown
of ZNF668. Percentage of cells with damaged DNA (tail moment greater than 1)
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in control cells without IR exposure was set as 1. At least 100 cells were scored
in each sample and each value represents the mean ± SD of three independent
experiments; Student t-test.

6.3

ZNF668 affects HR repair of DNA double strand breaks.
In mammalian cells, homologous recombination (HR) is one of major

conserved pathways involved in DSB repair. To confirm ZNF668’s role in DSB
repair, we analyzed ZNF668-deficient cells using an HR repair analysis system.
In this system, DSB was generated by the introduction of I-SceI enzyme and the
HR repair efficiency was reflected by the induced-GFP+ signal. We found
ZNF668 knockdown cells showed a significant decrease (30%) in HR repair
induced-GFP+ cells, indicating defective HR repair (Figure 28A). To rule out the
possibility that ZNF668 status may affect the access of I-SceI to chromatin DNA,
we detected I-SceI-induced cutting efficiency by semi-quantitative PCR analysis
over a time course by using a primer pair to amplify only the uncut I-SceI locus.
The I-SceI cutting efficiency was similar in ZNF668-containing and ZNF668deficient cells (Figure 28B).
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Figure 28. Impaired HR results from the loss of ZNF668. (A) ZNF668-depletion
impaired HR repair. ZNF668-depleted cells transfected with ZNF668 siRNA #1
and siRNA smartpool were subjected to HR repair analysis. Each value is
relative to the percentage of GFP+ cells in I-SceI-transfected cells with control
siRNA transfection, which was set to 1 and represents the mean ± SD of three
independent experiments; Student’s t-test. (B) Cutting efficiency of I-SceI was
detected by semi-quantitative PCR using a primer pair flanking the DSB site.
ZNF668 knockdown cells exhibited no differences in PCR products when
compared to control cells at different time points, suggesting similar cutting
efficiency of I-SceI in ZNF668 knockdown and control cells.

Furthermore, ZNF668-deficient and ZNF668-containing cells showed
similar cell-cycle profiles (Figure 29A), indicating that loss of ZNF668 didn’t alter
cell-cycle position during I-SceI cleavage. Moreover, transfection of ZNF668containing and ZNF668-deficient cells with a control GFP-expressing vector
(pEGFP-C1) resulted in similar numbers of GFP-positive cells (Figure 29B),
indicating that the lower frequency of repaired GFP+ cells in ZNF668-deficient
cells was not due to a lower transfection efficiency.
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Figure 29. Cell cycle profiles and transfection efficiency of ZNF668-depletion
cells with I-SceI transfection. (A) Cell cycle profiles of cells that were analyzed
for HR repair efficiency. ZNF668 knockdown didn’t affect cell cycle distribution.
(B) Transfection efficiency was monitored by using a control GFP-expression
vector (pEGFP-C1) in indicated cells. ZNF668 knockdown and control cells
showed similar transfection efficiency (~40%).
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To further test whether the defective HR repair in ZNF668 knockdown
cells is specific due to the lack of ZNF668, ectopic siRNA-resistant FLAGZNF668 was introduced back to the ZNF668-depleted cells and it was able to
restore the HR repair efficiency (Figure 30). All together, our data reveal a
critical function of ZNF668 in HR repair.

Figure 30. siRNA resistant Flag-ZNF668 restores the defective HR repair in
ZNF668-depleted cells. Each value is relative to the percentage of GFP+ cells in
I-SceI-transfected cells with control siRNA transfection, which was set to 1 and
represents the mean ± SD of three independent experiments. Western blotting
analyses to demonstrate the effective ZNF668 knockdown and Flag-ZNF668
overexpression were shown next to the graph.
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6.4

ZNF668 doesn’t affect ATM/ATR DNA damage detection and

signaling.
To test whether DNA-damage detection and signaling is affected in cells
lacking ZNF668, we investigated the ATM and ATR signaling pathway after IR or
UV irradiation treatment. Treatment with IR induced ATM and Chk2
posphorylation at similar levels in ZNF668-containing and ZNF668-defecient
cells (Figure 31A and B).

Figure 31. ZNF668-depletion doesn’t affect DNA-damage sensing or signaling.
(A and B) ZNF668-depletion didn’t affect ATM/Chk2 activation. ZNF668containing and ZNF668-depletion U2OS cells were exposed to IR irradiation
(10Gy) and cell lyses were prepared at the indicated time points after treatment.
Cell lyses were subjected to Western blot analyses and immunoblotted with
antibodies against the indicated molecules. (A) ATM phosphorylation and (B)
Chk2 phosphorylation were analyzed.

In parallel, IR induced phosphor-ATM foci were indistinguishable in
ZNF668-containing and ZNF668-defecient cells (Figure 32A), indicating that
ATM auto-activation and downstream events occur normally in cells lacking
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ZNF668. In addition to ATM/Chk2 pathway, UV induced Chk1 phosphorylation
showed similar levels in both ZNF668-containing and ZNF668-deficient cells
(Figure 32B).

Figure 32. ZNF668-depletion doesn’t affect ATM activation and ATR/Chk1
activation. (A) p-ATM foci formation after DNA damage treatment. ZNF668containing and ZNF668-depletion U2OS cells were exposed to irradiation and
stained with phoshoprylated ATM, counterstained with DAPI. (B) ZNF668depletion didn’t affect ATR/Chk1 activation. ZNF668-containing and ZNF668depletion U2OS cells were exposed to UV irradiation (50J/m2) and cell lyses
were prepared at the indicated time points after treatment. Cell lyses were
subjected to Western blot analyses and immunoblotted with antibodies against
the indicated molecules.

Moreover, the phoshporylation of H2AX was similarly induced in ZNF668deficient and ZNF668-containing cells after irradiation (Figure 33). These data
suggest that the inefficient HR repair in ZNF668-deficient cells is probably not
caused by the defects in the DNA-damage signaling cascade.
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Figure 33. Analysis of histone H2AX phosphorylation following DNA damage in
cells lacking ZNF668. ZNF668-containing and ZNF668-depletion U2OS cells
were exposed to irradiation and cell lyses were prepared at the indicated time
points after treatment. Cell lyses were subjected to Western blot analyses and
immunoblotted with antibodies against the indicated molecules. H2AX
phosphorylation was analyzed.

6.5

ZNF668 affects efficient activation and loading of repair proteins at

sites of DNA damage.
Next, we tested whether ZNF668 depletion impair DNA repair proteins
recruitment to DNA damage site. Replication protein A (RPA) is one of the key
participants in DSB repair. The RPA phospholylation was significantly decreased
in ZNF668 deficient cells without affecting the total RPA level (Figure 34A). In
parallel, the foci formation of p-RPA decreased in ZNF668-deficient cells (Figure
34B).
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Figure 34. ZNF668 depletion impairs RPA34 phosphorylation. (A) ZNF668
depletion impairs RPA34 phosphorylation. U2OS cells were transfected with
siRNAs targeting ZNF668, and the knockdown cells were treated with UV
radiation (50 J/m2). Cell lysates were harvested 3 h later and immunoblotted with
antibodies against the indicated molecules. (B) ZNF668 is required for phosphoRPA34 foci formation. (Left) Representative immunostaining images. Scale bar
is 10 μM. (Right) The bar graph represents the mean ± SD of three independent
experiments; Student’s t-test. At least 50 cells were scored in each sample.
Western blot analyses to demonstrate the effective ZNF668 knockdown were
shown next to the graph.
We also found that the foci formation of both RPA and Rad51 were
decreased (Figure 35A and B), indicating ZNF668 contributes to DNA repair
protein activation and recruitments to DNA damage site to perform repair
function.
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Figure 35. ZNF668 depletion impairs DNA repair protein foci formation. (A)
ZNF668 is required for RPA34 foci formation. (Left) Representative
immunostaining images. Scale bar is 10 μM. (Right) The bar graph represents
the mean ± SD of three independent experiments; Student’s t-test. At least 50
cells were scored in each sample. (B) ZNF668 is required for Rad51 foci
formation. (Left) Representative immunostaining images. Scale bar is 10 μM.
(Right) The bar graph represents the mean ± SD of three independent
experiments; Student’s t-test. At least 50 cells were scored in each sample.
Western blot analyses to demonstrate the effective ZNF668 knockdown were
shown next to the graph.

6.6

ZNF668 affects association of DNA repair proteins with chromatin.
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To test whether ZNF668 itself is a chromatin associating protein,
chromatin fraction was extracted and tested. As shown by Figure 36A,
endogenous ZNF668 was enriched in chromatin fractionation. Moreover, the
recruitment of DNA repair proteins to chromatin was also impaired. The
chromatin binding of p-RPA and RPA were impaired in ZNF668-deficient cells
(Figure 36B). Interestingly, endogenous ZNF668 associated with RPA34,
indicating ZNF668 might serve as a platform to recruit DNA repair proteins to
chromatin (Figure 36C).

Figure 36. ZNF668 depletion impairs association of DNA repair proteins with
chromatin. (A) ZNF668 is a chromatin association protein. Chromatin
fractionation was extracted from U2OS cells and cell lysate was subjected to
Western blot analyses. (Input) total cell lysate in Urea buffer; (Cyto) cytosolic
fraction; (Non-Chr) Non-chromatin association fraction; (Chr) Chromatin fraction.
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(B) ZNF668 depletion impaired recruitment of DNA repair proteins to chromatin.
ZNF668-containing and ZNF668-depletion U2OS cells were exposed to UV or
IR. The chromatin fraction was prepared at the indicated time post-irradiation
and subjected to Western blot analyses. (C) Endogenous ZNF668 associates
with RPA34. Cellular lysates of U2OS cells were prepared by lysing the cells
with RIPA buffer; immunoprecipitated with anti-ZNF668, anti-RPA34 or
preimmune IgG; and immunoblotted with antibodies against the indicated
molecules.

6.7

Chromatin modification agents improve activation of DNA repair

proteins.
Since chromatin modification is important for the recruitment of DNA
repair proteins to the DNA damage site, we suspect that the impaired
recruitment of DNA repair proteins to DSB sites in ZNF668 depletion cells is due
to the lack of efficient chromatin modification. To test this hypothesis, firstly, we
tested whether chromatin modification reagents (sodium butyrate, NaB or
trichostatin A, TSA) can reverse the effects of ZNF668 depletion on DNA repair
protein activation and recruitments to DNA damage sites. The treatment of
chromatin modification agents significantly reversed the effects of ZNF668
depletion on RPA phosphorylation and foci formation (Figure 37A, B and C).
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Figure 37. Chromatin modification agents improve activation DNA repair protein
RPA. (A) Sodium butyrate (NaB) or trichostatin A (TSA) -induced chromatin
modification restored the effect of ZNF668-depletion on RPA phosphorylation.
ZNF668 knockdown cells were exposed to 50 J/m2 of UV irradiation in the
presence or absence of chromatin modification reagents (NaB, 5 Mm; TSA, 200
ng/ml). Cell lysates were prepared and subjected to Western blotting analysis 3
hr after irradiation. (B) Sodium butyrate (NaB)-induced chromatin modification
improved p-RPA34 foci formation in ZNF668-depletion cells. ZNF668
knockdown cells were exposed to 50 J/m2 of UV irradiation in the presence or
absence of NaB. Cells were prepared and subjected to immunostaining 3 hr
after irradiation. Representative immunostaining images. Scale bar is 10 μM. (C)
Quantitative analysis of p-RPA34 foci induced in ZNF668-depletion cells from
multiple experiments. At least 50 cells were scored in each sample. Western
blotting analysis showed the effective ZNF668 knockdown in the cells was
shown above the graph.
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Consistently, the treatment of chromatin modification agents also
significantly reversed the effects of ZNF668 depletion on Rad51 foci formation
(Figure 38A and B).

Figure 38. Chromatin modification agents improve activation of DNA repair
protein RAD51. (A) Sodium butyrate (NaB)-induced chromatin modification
improved Rad51 foci formation in ZNF668-depletion cells. ZNF668 knockdown
cells were exposed to 10Gy of IR irradiation in the presence or absence of NaB.
Cells were prepared and subjected to immunostaining 3 hr after irradiation.
Representative immunostaining images. Scale bar is 10 μM. (B) Quantitative
analysis of Rad51 foci induced in ZNF668-depletion cells from multiple
experiments. At least 50 cells were scored in each sample.

Furthermore, the treatment of chromatin modification agents recovered
RPA and p-RPA recruitment to the chromatin (Figure 39A). The reduced HR
repair efficiency in ZNF668 knockdown cells was reversed in the presence of
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chromatin modification agents (Figure 39B). These data indicate that the
impaired HR repair and compromised recruitment of DNA repair proteins is a
direct consequence of impaired access to chromatin in ZNF668-deficient cells.

Figure 39. Chromatin modification agents improve recruitment of DNA repair
proteins to chromatin and recover HR repair. (A) Sodium butyrate (NaB)-induced
chromatin modification improved chromatin-associated p-RPA34 and RPA34 in
ZNF668-depletion cells. ZNF668 knockdown cells were treated with 50 J/m2 of
UV irradiation in the presence or absence of sodium butyrate (5mM). Three
hours after treatment, chromatin-enriched fractions were subjected to Western
blot analysis. (B) Sodium butyrate (NaB) or trichostatin A (TSA) -induced
chromatin modification restored the impaired HR repair in ZNF668-depletion
cells. ZNF668-depleted cells were subjected to HR repair analysis in the
presence or absence of chromatin modification reagents. Each value is relative
to the percentage of GFP+ cells in I-SceI-transfected cells with control siRNA
transfection, which was set to 1 and represents the mean ± SD of three
independent experiments; Student’s t-test.

6.8

ZNF668 depletion impairs histone H2A acetylation
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Histone acetylation is important for chromatin modification after DNA
damage response. Since we observed that the compromised HR repair in
ZNF668 deficient cells was associated with impaired chromatin access for repair
proteins, we reasoned that this may be due to impaired regulation of histone
acetylation in the absence of ZNF668.
To test this, we examined the histone acetylation in ZNF668 depletion
cells. We found that both the overall and IR-induced H2A K5 acetylation in
whole cell lysates (extracted by SDS sample buffer) were affected by ZNF668
depletion (Figure 40), which indicated that ZNF668-mediated H2A acetylation
may have a role in DSB repair.

Figure 40. Analysis of histone H2A acetylation following DNA damage in cells
lacking ZNF668. ZNF668-containing and ZNF668-depletion U2OS cells were
exposed to irradiation and cell lyses were prepared at the indicated time points
after treatment. Cell lyses were subjected to Western blot analyses and
immunoblotted with antibodies against the indicated molecules. H2A acetylation
was analyzed.
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Next, we examined whether the chromatin modification reagents can
recover ZNF668’s effect on the impaired H2A acetylation at K5 site. The
treatment of chromatin modification agents significantly reversed the effects of
ZNF668 depletion on H2A acetylation at the K5 site after IR treatment (Figure
41).

Figure 41. Chromatin modification reagents sodium butyrate (NaB) or
trichostatin A (TSA) -induced chromatin modification restored the effect of
ZNF668-depletion on H2A acetylation after IR. ZNF668 knockdown cells were
exposed to 10Gy of IR irradiation in the presence or absence of chromatin
modification reagents (NaB, 5 Mm; TSA, 200 ng/ml). Cell lysates were prepared
and subjected to Western blotting analysis 2 hr after irradiation.

The acetylation site K5 is conserved in H2A and its viarant H2AX.
Previous studies showed H2AX K5 is the target of acetylation upon DSBs in the
chromatin because the IR-induced acetylation was abolished by the H2AX (K5R)
mutation (Ikura et al., 2007). To clarify whether H2AX acetylation is the target of
ZNF668 regulated acetylation process, we overexpressed Flag-H2AX in U2OS
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cells and pull down the Flag-H2AX protein complex by immunoprecipitation. The
Flag-H2AX acetylation was detected with K5 acetylation antibody. As shown in
Figure 42, we found that H2AX K5 acetylation was induced by IR treatment and
in ZNF668 depletion cells, the K5 acetylation of H2AX was significantly reduced.
These data are consistent with the previous finding and indicate that ZNF668 is
important for efficient H2AX K5 acetylation after IR DNA damage.

Figure 42. ZNF668 depletion impairs IR induced H2AX acetylation. U2OS cells
were transfected with control or ZNF668 siRNA; 24h later, cells were transfected
with empty vector or Flag-H2AX; 48 h later, cells were exposed to IR treatment
and cells were harvest at indicated time post-IR treatment. (A) Total cell lysates
were subjected to western blotting analysis to confirm efficient ZNF668
knockdown. (B) The cell lysates (1.5 mg) were immunoprecipitated and
immunoblotted with antibodies against the indicated molecules.

6.9

ZNF668 depletion impairs histone H2AX acetylation by regulating

Tip60-H2AX interaction.
Histone H2AX acetylation plays a role in the selective histone variant
exchange, which is important for chromatin structure regulation at DNA damage
sites (Kusch et al., 2004). Since we observed decreased histone H2AX
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acetylation in ZNF668-depletion cells, we suspect that ZNF668 is important for
histone H2AX acetylation and chromatin structure regulation.
To test how ZNF668 regulates H2AX acetylation, firstly we tested whether
ZNF668 interacted with H2AX. As shown in Figure 43, immunoprecipitation
analysis showed that H2AX interacted with ZNF668.

Figure 43. ZNF668 associates with H2AX. U2OS cells were transfected with
empty vector or Flag-ZNF668; 48 h later, cells lysates (3 mg) were
immunoprecipitated and immunoblotted with antibodies against the indicated
molecules.
Previous studies have shown that K5 of histone H2A is acetylated by
Tip60 in vitro (Kimura et al., 1998). The interaction between Tip60 and H2AX is
IR-induced. After IR treatment, Tip60 specifically binds to H2AX but not H2A and
facilitates H2AX K5 acetylation (Ikura et al., 2000). Since we observed
decreased acetylation of H2AX K5 in ZNF668 depletion cells after IR, we
suspect that ZNF668 regulates H2AX acetylation through the regulation of
Tip60-H2AX protein complex. To test this, firstly, we tested whether ZNF668
regulates Tip60 expression. As shown in Figure 44A, Tip60 protein level didn’t
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change in ZNF668-depletion cells with or without IR treatment. Chromatin
fractionation analysis also showed that the chromatin associated Tip60 didn’t
change with ZNF668 knockdown and IR treatment (Figure 44B).

Figure 44. Tip60 expression and chromatin association in ZNF668-depletion
cells. (A) ZNF668 depletion didn’t impair Tip60 expression with or without IR.
ZNF668-containing and ZNF668-depletion U2OS cells were exposed to IR. Total
cell lysate were harvested in urea buffer at the indicated time points and
subjected to Western blot analyses. (B) Tip60’s association with chromatin were
similar in control and ZNF668-depletion cells. ZNF668-containing and ZNF668depletion U2OS cells were exposed to IR. The chromatin fraction was prepared
and subjected to Western blot analyses.

To test whether the reduced H2AX acetylation in ZNF668-deficient cells is
due to the decreased interaction between Tip60 and H2AX proteins, we did
immunoprecipitation assay of FLAG-H2AX protein complex. As shown in Figure
45A, the interaction between H2AX and Tip60 was induced by IR treatment in
control cells, which was consistent with previous finding (Ikura et al., 2007).
However, ZNF668-depletion impaired the IR-induced interaction between Tip60

82

and H2AX, indicating ZNF668 is required for facilitating Tip60 interaction with
H2AX to acetylate H2AX after DNA damage treatment (Figure 45B).

Figure 45. ZNF668 depletion impairs IR induced Tip60-H2AX interaction. (A)
U2OS cells were transfected with Flag-H2AX and exposed to IR treatment 48
hours after transfection. Cell lysates were harvested at indicated time post-IR
treatment and subjected to immunoprecipitation and immunoblotting. (B) U2OS
cells were transfected with control or ZNF668 siRNA; 24h later, cells were
transfected with empty vector or Flag-H2AX; 48 h later, cells were exposed to IR
treatment and cells were harvest at 30 minutes post-IR treatment. The cell
lysates (1.5 mg) were immunoprecipitated and immunoblotted with antibodies
against the indicated molecules.
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6.10

Discussion
In this part of study, we studied the function of ZNF668 in DNA damage

response pathways. Our data indicated that ZNF668 didn’t affect the initiation
and signaling cascade of DNA damage pathway. However, ZNF668 participated
in DNA damage repair. The inefficient DNA repair in ZNF668 depletion cells
caused prolonged DNA damage and genetic instability.
Chromatin modification is important for efficient DNA damage repair
proteins’ recruitment to the damage sites. Our data showed that ZNF668 is a
chromatin associating protein (Figure 36A) and it interacts with histone variant
H2AX (Figure 43). ZNF668 didn’t affect H2AX activation but it affects histone
H2AX acetylation upon DNA damage treatment, which is important for the open
of chromatin structure upon DNA damage treatment and the access of repair
proteins to the damaged DNA. Therefore, our results suggest a model for
ZNF668 function in double strand break repair. ZNF668 promotes chromatin
modification and in turn facilitates the recruitment of DNA repair proteins to DNA
lesions for efficient repair. Loss of ZNF668 would lead to impaired chromatin
modification and DNA DSB repair, which may contribute to the development of
cancer.
Our findings also reveal a mechanism by which ZNF668 regulates
chromatin modification. Different types of histone acetylase are responsible for
the acetylation of different histones (Tsukuda et al., 2005; Ziv et al., 2006;
Peterson et al., 2000). With DNA damage, the Tip60 acetylase is recruited to
DNA lesions by other molecules to recognize histone H2AX and induce H2AX
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modifications. Our studies demonstrate that ZNF668 is necessary for the
recruitment of Tip60 to the DNA damage site to perform its function on H2AX
acetylation. Therefore it will be of future interests to address the underlying
mechanism of ZNF668 regulation on Tip60-H2AX complex and illustrate the
additional roles of ZNF668 in the regulation of Tip60-H2AX complex in response
to DNA double strand breaks induced by DNA damage.
The present study shows that ZNF668 participates in homologous
recombination repair by regulating histone modification and chromatin
remodeling. We propose a model (Figure 46) to explain the mechanism of
ZNF668 in regulation of DNA repair. ZNF668 is a chromatin association protein.
When the double strand breaks are induced by DNA damage treatment, ZNF668
binds to histone H2AX around the DSBs. The protein complex of ZNF668-H2AX
serves as a platform to recruit HAT-Tip60 to the DSBs. Then Tip60 acetylates
H2A that surrounds DNA breaks. Acetylated histones facilitate access and
binding of DNA repair proteins to chromatin DNA. After DNA repair is completed,
the chromatin is reassembled. It has been shown that HAT complexes are
related to cancer development because they are important for transcription
regulation and regulation of DNA damage response (Cairns et al., 2001; Yang et
al., 2004). Therefore, our studies identify a novel factor with the potential to
regulate histone acetylation and chromatin remodelling during DNA repair and to
maintain genomic stability.
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Figure 46. A schematic model for the role of ZNF668-mediated histone
acetylation and chromatin reconfiguration in DNA repair.
Together, these results indicate that ZNF668 participates in chromatin
modification and reconfiguration, which facilitate access of the repair machinery
to the site of DNA breaks. However, further experiments will be needed to
emphasize the role of ZNF668 in DNA double strand break repair. In addition to
the DNA damage induced H2A acetylation, we also observed an overall
decrease of H2A acetylation in ZNF668 deficient cells without DNA damage,
indicating ZNF668 may also participate in the regulation of global acetylation. To
further clarify the role of ZNF668 in DNA Damage site modification or global
modification, chromatin immunoprecipitation (ChIP) and PCR techniques can be
used to determine the recruitment of specific molecules such as Tip60,
acetylated H2AX, acetylated H3 and H4 to the double strand break sites. The
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U2OS cells that used in our study to study the HR repair provides us a useful
tool to investigate the status of specific proteins in DSB sites. The DSB can be
induced by I-SCE enzyme transfection and the primers flanking the DSB sites
can be used to analyze the recruitment of proteins to the DSB sites after ChIP.
In this study, we emphasized on the acetylation status of K5 site in H2AX
in ZNF668 deficient cells because the role of H2AX K5 acetylation in DNA repair
has been reported previously. However, there are other acetylation sites in
H2AX such as K9. It is important to determine whether ZNF668 affects other
sites of H2AX acetylation. This ambiguity can be resolved by examining sitespecific mutants in the histone proteins themselves. For example, K5 or K9 sitespecific H2AX mutants can be generated through site-directed mutagenesis and
the acetylation status of mutant H2AX can be studied under DNA damage
treatment with or without ZNF668 expression.
In addition, our study doesn’t rule out the possible role of ZNF668 on
other core histones’ acetylation. Many histone modifying enzymes have broad
substrate specificities. For example, Tip60 can acetylate both H2A and H4. Due
to this reason, it is difficult to discern the contributions of other histone
acetylation to DNA repair. It is unclear whether ZNF668 regulates DNA repair
through the regulation of Tip60’s acetylation effects on H2A or other histones.
Antibodies specific to site-specific modifications of each core histone can be
used to perform ChIP and PCR analyses to clarify the recruitment of histones to
the DSB sites in ZNF668 deficient cells. Moreover, future experiments will be
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needed to identify the possibility of ZNF668’s effect on other type of histone
modifications.
Tumorigenesis is driven by the direct or indirect effects from the genetic
alterations in oncogenes and tumor suppressor genes. Our studies indicate
ZNF668 is a potential tumor suppressor. In addition to the mutation inside
ZNF668, it can also regulate other important genes involved in multiple
pathways which are necessary for normal cell growth. These results make
ZNF668 a potential therapeutic target for human breast cancer. Therefore, the
novel findings from this project have both the potential to improve our
understanding of genetic mechanisms underlying breast cancer and also the
likelihood of novel approaches to the treatment of breast cancer.
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